




Roberto Plebani*,3, Gavin R. Oliver†,3,
Marco Trerotola*,4, Emanuela Guerra*,
Pamela Cantanelli*, Luana Apicella*,
Andrew Emerson‡, Alessandro Albiero§,
Paul D. Harkin†,¶, Richard D. Kennedy†,¶
and Saverio Alberti*,#
*Unit of Cancer Pathology, Centre of Excellence for Research
on Aging, “G. D’Annunzio” University Foundation, Chieti, Italy;
†Almac Diagnostics, Craigavon, United Kingdom; ‡CINECA,
Bologna, Italy; §BMR Genomics, Padova, Italy; ¶Centre for
Cancer Research & Cell Biology, Queen’s University, Belfast,
United Kingdom; #Department of Neuroscience and Imaging,
“G. d’Annunzio” University of Chieti-Pescara, Chieti, Italy
Abstract
mRNA chimeras from chromosomal translocations often play a role as transforming oncogenes. However, cancer
transcriptomes also contain mRNA chimeras that may play a role in tumor development, which arise as transcrip-
tional or post-transcriptional events. To identify such chimeras, we developed a deterministic screening strategy for
long-range sequence analysis. High-throughput, long-read sequencing was then performed on cDNA libraries from
major tumor histotypes and corresponding normal tissues. These analyses led to the identification of 378 chimeras,
with an unexpectedly high frequency of expression (≈2 × 10−5 of all mRNA). Functional assays in breast and ovar-
ian cancer cell lines showed that a large fraction of mRNA chimeras regulates cell replication. Strikingly, chimeras
were shown to include both positive and negative regulators of cell growth, which functioned as such in a cell-type–
specific manner. Replication-controlling chimeras were found to be expressed by most cancers from breast, ovary,
colon, uterus, kidney, lung, and stomach, suggesting a widespread role in tumor development.
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Introduction
Several chimeric transcripts have been discovered in human solid
tumors, which derive from chromosomal translocations. These often
encode structurally and functionally altered signaling molecules or
transcription factors [1] or may also function as non-coding RNA
[2]. More than half of prostate cancers harbor fusion sequences, mostly
TMPRSS-ERG [3]. The SLC45A3-ELK4 (ETS family) fusion tran-
script can be generated both by chromosomal rearrangement and by
trans-splicing, and it was found to be expressed in both normal prostate
tissue and in prostate cancer. High levels of SLC45A3-ELK4 mRNA
are restricted to a subset of prostate cancer samples [4]. A small inver-
sion within chromosome 2p leads to the formation of a fusion gene
comprising EML4 and ALK in non–small cell lung cancer [5]. The
fusion of MAML2 with CRTC1 or CRTC3 has a role in the develop-
ment of mucoepidermoid carcinomas [6]. Rearrangements of RAF
pathway members occur in prostate and gastric cancers [7], and a para-
centric inversion of chromosome 7q results in an in-frame fusion
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between exons 1 and 8 of the AKAP9 gene and between exons 9 and 18
of BRAF in radiation-induced papillary carcinomas [8]. Other thyroid
carcinoma–specific events include fusion of the RET oncogene to var-
ious partners [9]. Further oncogenic fusions have been detected in other
solid tumors [10,11].
Cancer transcriptomes also contain mRNA chimeras that arise as
transcriptional (long intergenic transcription) or post-transcriptional
(trans-splicing [12]) events that may play a role in tumor develop-
ment. Previous findings showed that oncogenic transcripts can indeed
be generated post-transcriptionally [13–15]. The fusion of CYCLIN
D1 mRNA to TROP2 transcripts generates oncogenic CYCLIN D1-
TROP2 chimeras, whose tumor-promoting function is induced with a
dramatically increased mRNA stability [13]. The oncogenic JAZF1-
JJAZ1 chimeric mRNA can be originated by trans-splicing as well as
by a chromosomal translocation [14]. Similarly, the SLC45A3-ELK4
chimeric transcript can be generated in the absence of chromosomal
rearrangements [4,16]. Intergenic splicing generates a ubiquitous
chimeric mRNA between the P2Y11 and SSF1 transcripts [17]. The
generation of these chimeras appears as a regulated event [13,14] and
was shown to also occur in normal tissues [4,13,14,17–20]. Several of
these chimeric transcripts have been used as diagnostic or prognostic
[21] markers and as targets for anti-neoplastic therapy [10,13,22,23].
Screening strategies were previously developed for in silico iden-
tification of mRNA chimeras in cancer cells [24]. Next-generation
sequencing (NGS) approaches now provide much larger sequence
information for chimera discovery [7,19,20,25–27]. However, most
second-generation NGS approaches generate highly multiplexed,
short-tag sequence reads, which are then condensed in strings of
base-call probabilities, through a probabilistic fitting of massively
parallel data sets. This makes contig assemblies and target alignments
correspondingly more difficult [19,25,27,28]. Alignments to com-
plex genomes are even more hampered, because of higher sequence
complexity [29] and homology within closely related gene families
and pseudogenes.
These problems have led to significant efforts for achieving longer
sequence reads and higher sequencing accuracy. In 2005, 454 launched
the first NGS apparatus, which was able to generate 100-bp reads.
Sequence reads extended to 200 bp in 2007 [30] and are close to
900 bp at present [31]. SOLID sequencing generated 35-bp reads in
2007 [30], and this extended to 75 bp in 2011 [32]. Illumina generated
36-bp sequence reads in 2006 to 2008 [30]. These extended to 100 bp
in 2010 [31] and to 300 bp in 2012 (www.illumina.com). Ion Torrent
introduced its first sequencer at the end of 2010, and this was capable of
100-bp-long reads. As of 2012, reads of 525-bp average length have been
obtained (www.iontorrent.com/lib/images/PDFs/pe_appnote_v12b.pdf ).
Pacific Biosciences (www.pacificbiosciences.com) succeeded in obtain-
ing even longer reads, which currently are up to 1500 bp.
To take advantage of these technical advances, we have developed
an analytical strategy for high-accuracy identification of mRNA chi-
meras in long-read DNA sequence data sets (Figure 1). This strategy
was shown to work efficiently for chimera recognition (Tables S1–S7
and Figure S1). High-throughput, long-read sequencing was then
performed on cDNA libraries from major tumor histotypes and
corresponding normal tissues. This led to the identification of 378 chi-
meras, from both normal and transformed cells, indicating an
unexpectedly high frequency of expression (≈2 × 10−5 of all mRNA).
Functional assays in breast and ovarian cancer cell lines showed that a
large fraction of mRNA chimeras regulate cell replication. Strikingly,
chimeras were shown to include both positive and negative regulators
of cell growth, which functioned as such in a cell-type–specific manner.
Replication-controlling chimeras were found to be expressed by most
cancers from breast, ovary, colon, uterus, kidney, lung, and stomach,
suggesting selective pressure for a role in tumor development.
Materials and Methods
Cells
Human MCF-7, MCF-7/Almac, HBL-100, SK-BR-3, MDA-MB-
231, MDA-MB-361, MDA-MB-415, MDA-MB-453, MDA-MB-
468, HS578, and ZR751 breast cell lines and SKOV-3, IGROV-1,
OVCAR-3, and OVCA-432 ovarian cancer cell lines were grown in
RPMI 1640 medium supplemented with 10% FBS, 100 IU/ml penicil-
lin, and 100 μg/ml streptomycin (Euroclone, Milan, Italy). All cell lines
were obtained from ATCC (LGC Standards, Teddington Middlesex,
United Kingdom) where they were authenticated by standardized pro-
cedures (www.atcc.org).
Cell Growth Assays
MCF-7, HBL-100, SK-OV-3, IGROV-1, and OVCAR-3 cells were
seeded at 1 × 103 to 10 × 103 cells/well in 96-well plates (five replicates
per data point). Cell numbers were quantified by staining with crystal
violet [33]. Standard growth curves for each cell line were generated by
seeding two-fold serial dilutions of defined cell numbers. Crystal violet
standard curves showed good linear responses (R2 > 0.998, in all cases)
(Figure S2). To support the crystal violet readings, quantification was
also performed by image analysis (ImageJ). Digital pictures were taken
from 96-well plates after fixation. Picture noise was removed with
GIMP software, after random sampling of cell-free pixels. ImageJ anal-
ysis was then performed by quantifying black areas in each culture well
after image conversion to a gray scale (manuscript in preparation).
DNA Transfection
Cells were transfected with DNA in Lipofectamine 2000 (HBL-
100, SKOV-3, IGROV-1, and OVCAR-3 cells) or LTX (Invitrogen,
San Diego, CA), which was found to be optimal for MCF-7 cells (Fig-
ure 5C ) [34], following themanufacturer’s instructions. pEYFP transfec-
tion was used to quantify transfection efficiency [35] (EYFP expression,
as measured by flow cytometry).
Flow Cytometry Immunofluorescence
Flow cytometry analysis was performed as described previously [36,37],
on fluorescence-activated cell sorters (FACSCalibur, Becton-Dickinson,
Sunnyvale, CA). To improve the detection of EYFP transfectants, we
performed subtraction of cell autofluorescence and displacement of true
transfectants in the red channel as described [35,38].
Human Samples for Tumor Transcriptome Sequencing
Non–small cell lung cancer. Non–small cell lung cancer libraries
were generated from a set of frozen tissue samples, comprising 65 tumor
samples (30 adenocarcinomas, 20 squamous cell carcinomas, and 15
other morphologies) from the Roy Castle Lung Cancer Research
Institute (University of Liverpool) and Queens University Belfast. To
maximize chances of mRNA chimera discovery, we proceeded to
generate libraries from both tumor and normal tissues. Normal lung
RNA was obtained from multiple commercial suppliers (Clontech,
Palo Alto, CA; Ambion, Austin, TX; BioCat, Heidelberg, Germany;
Stratagene, La Jolla, CA; Cybridi, Rockville, MD; and OriGene,
Rockville, MD), overall from 16 donors of different ethnicity.
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Ovarian cancer. Ovarian library A comprised 64 ovarian tumors
(31 serous, 14 endometroid, 6 mucinous, 5 clear cell, and 8 undiffer-
entiated cancers; 52 were stage III/IV and 12 were stage I/II). For
ovarian library B, RNA from normal ovarian tissue was obtained from
commercial suppliers (Ambion and AMS Biotechnology [Bioggio,
Switzerland]). The library was generated with equal quantities of RNA
from different ethnicities (Asian, Caucasian, and African-American),
with 23 donors overall. For ovarian library C, ovarian tumor total
RNA was obtained from various commercial suppliers (Ambion,
Clontech, Cytomyx [Lexington, MA], Biocat, and Asterand [Detroit,
MI]). The library was composed of equal quantities of RNA of
different ethnicity (Asian, African-American, and Caucasian), with
37 donors overall.
Prostate cancer. The prostate cancer library was constructed from
30 tumors (74% Caucasian and 26% African-American), 8 normal
prostate RNA supplied by Clontech, AMS Biotechnology, and Cybridi,
and 56 normal tissues adjacent to tumors obtained from St. Vincents
Hospital (Dublin, Ireland).
Breast cancer. The breast cancer library was composed of 90 tumors
and 18 normal samples [39–41].
Colorectal cancer. The colorectal library comprised 40 tumor sam-
ples and 40 normal tissues.
Tumor Validation Sample Set
cDNA was synthesized from 25 human primary tumors (10 breast,
6 colon, 3 stomach, 2 ovary, 2 kidney, and 2 uterus), which were
independent from those used to construct the cDNA libraries. These
25 samples were used as a test set to validate chimera expression by
both conventional polymerase chain reaction (PCR)/sequencing and
real-time reverse transcription (RT)–PCR.
Figure 1. Flow diagram of chimera identification and validation steps.
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Normal Tissues
Normal breast, colon, uterus, prostate, placenta, lung, kidney,
pancreas, and stomach RNA were obtained from Clontech.
cDNA Library Construction
All of the frozen tumor tissues were homogenized in RNA STAT-
60 (Tel-Test, Friendswood, TX), and the RNA was extracted accord-
ing to the manufacturer’s instructions. Equal amounts of good quality
total RNA were pooled, and the mRNA was isolated using μMACS
mRNA isolation kits (Miltenyi Biotec, Bergisch Gladbach, Germany),
as described by the manufacturer. Lung cDNA libraries were con-
structed from 3 μg of mRNA using the CloneMiner cDNA library
construction kit (Invitrogen), according to the manufacturer’s instruc-
tions. cDNA were inserted in the pDONR 222 vector from Invitrogen.
Titer and average insert size in each cDNA library were determined
according to the manufacturer’s instructions. Plasmid preparations of
individual clones were carried out using a modified Montáge alkaline
lysis method (Millipore, Billerica, MA) that incorporates MultiScreen
Plasmid 384 Miniprep clearing plates for centrifugal lysate clearing.
Sequencing of cDNA Libraries
Colony sequencing automation was implemented (QPix colony
picker Biomek liquid handlers). Cycle sequencing reactions were per-
formed in 10-μl volumes using a 1/16 dilution of Big Dye Terminator
v3.1 ready reaction mix in Big Dye sequencing buffer (Applied Bio-
systems, Foster City, CA), 5 μMM13 primer, and 100 ng of template
DNA. Cycle sequencing was performed for 40 cycles at 95°C for
10 seconds, 50°C for 5 seconds, and 60°C for 2.5 minutes. Excess dye
terminators were removed using CleanSEQ (Agencourt Biosciences
Corporation, Beverly,MA). Sequencing plates were analyzed onApplied
Biosystems 3730/3730 × l DNA Analyzers using Applied Biosystems
Sequence Analysis software. M13 forward primers were used for
5′ end sequencing of the colorectal and breast libraries; M13 reverse
primers were used for 3′ end sequencing of the normal lung and pros-
tate libraries; bothM13 forward and reverse primers were used for 5′ and
3′ end sequencing of the lung tumor and ovarian cancer libraries.
Plasmids
The pEYFP expression vector (Clontech) was used to express YFP.
The pSUPER vector [42] was used for RNA interference.
Small Inhibitory RNA (siRNA)
siRNA design followed four complementary strategies, i.e., Tuschl
criteria (position in the mRNA, guanine-cytosine [GC] content, base
composition, and flanking sequences) [43], Invitrogen algorithms
(rnaidesigner.invitrogen.com/rnaiexpress/; sequence composition,
nucleotide content, thermodynamic properties, and experimental valida-
tion), Whitehead Institute screening procedures (jura.wi.mit.edu/bioc/
siRNAext/; Tuschl criteria, predictions of binding energies and BLAST
filtering of cross-hybridizing sequences) [44], and Sonnhammer searches
(www.sirnawizard.com/design_advanced.php; data mining on validated
siRNA databanks, using motif rules and energy parameters) [45].
Annealed siRNA oligos were subcloned into the pSUPER vector.
siRNA expression constructs were transiently transfected in MCF-7
and HBL-100 breast cancer cells and in SK-OV-3, IGROV-1, and
OVCAR-3 ovarian cancer cells. siRNA-targeted transcript levels were
quantified by real-time PCR. Negative-control siRNA directed toward
irrelevant targets were used; these were chosen after extensive testing
for lack of off-target influence on cell growth.
Quantitative RT-PCR
Hybrid sequences in cancer cell lines and tumor samples were
amplified by quantitative RT-PCR. One microgram of total RNA was
reverse transcribed with the M-MLV Reverse Transcriptase (Promega,
Madison, WI) according to standard protocols. cDNAwas quantified by
ethidium bromide fluorescence in solution [46]. Quantitative RT-PCR
was performed with an ABI-PRISM 7900HT Sequence Detection
System (PE Applied Biosystems, Foster City, CA), using Sybr Green as
the probe (Applied Biosystems). Samples were assayed as replicates (two
or three independent samples), and the 1.83−ΔΔCT method was used to
calculate the relative changes in gene expression [13]. The glyceraldehyde
3-phosphate dehydrogenase (GAPDH) housekeeping gene was used
as an internal control. For setup curves, ΔCT (CT, target gene − CT,
GAPDH) was calculated for each cDNA dilution. The data were fit
using least-squares linear regression analysis. As amplification efficiency
was linear over the range of RNA amounts used, amplification curves
were used to calculate crossover point values for siRNA-treated sam-
ples. To check for the correctness of amplified bands, amplification
products were run on 3% agarose gels. Amplified products were purified
and extensively sequenced (BMR Genomics, Padova, Italy). Quantita-
tive RT-PCR was also performed with PrimeTime IDT (Integrated
DNA Technologies, Bologna, Italy; www.idtdna.com) to reliably
detect with higher sensitivity the interchromosomal CHD2-CHMP1A
fusion in normal tissues.
Diagnostic PCR
Interchromosomal CHD2-CHMP1A and ADK-DHX8 and intrachro-
mosomal PRKAA1-TTC33, SAMM50-PARVB and P2RX5-TAX1BP3,
URB1-C21orf45, CTBS-GNG5, THC2538403 ZNF498-CUX1,
THC2523555 C9orf47-S1PR3, and THC2668182 KLH22-SCARF
were amplified in 10 breast and 4 ovarian cancer cell lines and in
25 tumor samples by nested PCR. Chimeric mRNA were amplified
by 35 amplification cycles (30 seconds at 94°C for denaturation,
30 seconds at 60°C for annealing, and 30 seconds at 72°C for exten-
sion).HotMaster Taq-polymerase 0.7 units (Eppendorf) and 12.8 pmol
of forward and reverse primers were used for the amplification
reaction. All of the amplified products were purified and sequenced
(BMR Genomics).
Statistical Analysis
Two-way analysis of variance and post-hoc Bonferroni t tests were used
for growth curve comparisons. Data were analyzed using Sigma Stat
(SPSS Science Software UK Ltd, Birmingham, United Kingdom) and
GraphPad Prism (GraphPad Software Inc, La Jolla, CA).
Results
Chimeric mRNA Detection Procedure
A procedure (FusionMiner) was designed to process BLAST analyses
of query sequences against genomic databanks, through sequential
stages of analysis and exclusion and pass-or-fail tests, as described in
the Supplemental Online Material (Figure 1 and Tables S1–S7). Fu-
sionMiner performance was assessed by screening the Dana Farber
Cancer Institute Gene Index Project tentative human consensus
(THC) collection (Figure S1) and long-sequence-read 454 Titanium
data sets (Supplemental OnlineMaterial). Samples of the identified chi-
meras were then validated by diagnostic PCR and by real-time quanti-
tative PCR analysis of cancer cell lines.
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Transcriptome Sequencing for Growth Regulatory
Chimera Discovery
To discover growth regulatory chimeras, we then performed a large-
scale sequencing and analysis of tumor and normal tissue transcriptomes.
To maximize chances of discovery of growth regulatory chimeras, both
major tumor histotypes, i.e., non–small cell lung, breast, prostate, ovary,
and colorectal cancers, and the corresponding normal tissues were ana-
lyzed. Long-sequence-read (900 bp on average) cDNA library data sets
were obtained: 481,765 from ovary, 485,049 from prostate, 157,259
from breast, 46,445 from colon, and 603,935 from lung.
These sequences were run through FusionMiner. Twenty-fivemRNA
chimeras were identified (15 intrachromosomal and 10 interchro-
mosomal; Table S8, Supplemental Sequence Data). All sequences were
shown to possess the structural characteristics of bona fide chimeric
mRNA [24] (Supplemental Sequence Data). Breast and ovarian chi-
meras were validated by RT-PCR and functional assays (see below).
These findings led to estimate absolute chimera frequencies as 1.4 ×
10−5 of all mRNA. This was in remarkable agreement with NGS
sequencing data (≈2 × 10−5) (Supplemental Online Material), indicat-
ing an unexpectedly high frequency of expression of chimeric mRNA.
Chimeric Transcript Expression in Cancer Cells
Expression of the nine chimeras from the breast library and of the
four chimeras from the ovarian library was analyzed in breast (MCF-7,
HBL-100, SK-BR-3, MDA-MB-231, MDA-MB-361, MDA-MB-
415, MDA-MB-453, MDA-MB-468, HS578, and ZR751) and ovar-
ian (SKOV-3, IGROV-1, OVCAR-3, and OVCA-432) cancer cell
lines (Figure 2 and Table S8). Six of the nine chimeras were successfully
amplified by RT-PCR (Figure 2A and Table S9). Amplification from
breast cancer cells was obtained for PRKAA-TTC33 (10/10 lines),
SAMM50-PARVB (5/10 lines), P2RX5-TAX1BP3 (3/10 lines), and
CHD2-CHMP1A (9/10 lines) (Figure 2A, left). All individual ampli-
cons were sequence verified (Figure 2C ). Three of these chimeras
were also detected in ovarian cancer cells: PRKAA-TTC33 (4/4 lines);
SAMM50-PARVB (3/4 lines), and CHD2-CHMP1A (4/4 lines)
(Figure S3).
The URB1-C21ORF45 and CTBS-GNG5 chimeras from the
ovarian library were identified in all four ovarian cancer cell lines
(Figure 2A, right). They were also detected in all breast cancer lines.
Notably, different cancer cells expressed different steady-state levels of
the chimeric mRNA, e.g., CTBS-GNGS was approximately 20 times
Figure 2. Chimeric mRNA expression in cancer cell lines. (A) Expression of chimeras discovered from tumor and normal tissue library
sequencing; agarose electrophoresis of nested or real-time PCR products. Breast and ovarian cancer cell lines are indicated; *SK-BR-3.
(B) URB1-C21ORF45 (top) and CTBS-GNG5 (bottom) expression in breast cancer cell lines by quantitative RT-PCR; results are expressed
as percent values (MCF-7 = 100); three replica samples were analyzed per data point. Bars, SD. (C) CHD2-CHMP1A. Sequence of the
PCR amplicon versus that of the chimera isolated from the breast library. (D) Structure of validated chimeric mRNA; 5′ partners (orange) and
3′ partners (green) are shown; exon junctions are indicated.
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less expressed in HBL-100 cells, as compared with MDA-MB-415
cells (Figure 2B ).
Overall, 75% of the THC chimeras and 54% of the chimeras from
breast and ovary libraries (Tumor Transcriptome Sequencing Project)
were detected in breast and ovarian cancer cell lines/primary tumors.
Fusion Proteins Encoded by the Growth Regulatory Chimeras
CHD2-CHMP1A. CHD2 encodes the chromodomain helicase
DNA-binding protein 2; CHMP1A encodes the chromatin-modifying
protein 1A. Of interest, both of these chimera partners encode proteins
with regulatory roles on chromatin/DNA structure. However, only the
first 20 amino acids of helicase DNA-binding protein 2 are retained in
the fusion-protein product (Table S11). This contains a casein kinase II
phosphorylation site (prosite.expasy.org/). One out-of-frame C-terminal
amino acid is provided by the chromatin-modifying protein 1A sequence
(Table S11) and generates a hybrid N-glycosylation site, although it is
not clear if this is processed in vivo.
CTBS-GNG5. CTBS encodes chitobiase;GNG5 encodes the di-N -
acetyl–binding and guanine-nucleotide–binding proteins. Chitobiase is
a lysosomal glycosidase that is involved in degradation of asparagine-
linked oligosaccharides on glycoproteins. It is also involved in the hydro-
lysis ofN -acetyl-β-D-glucosamine.GNG5 encodes the γ chain of trimeric
G proteins. A fusion mRNA between chitobiase and guanine-nucleotide–
binding protein was also identified by Akiva et al. [47] and by Nacu
et al. [26]. The CTBS-GNG5 is an “in-frame” fusion that preserves the
first 319 amino acids from the N-terminal partner and the last 41 amino
acids from the C-terminal partner (Table S11). CTBS provides an appar-
ently functional chitinase catalytic domain, with a formal glycosylation site
at S300. Most of Gγ5 is retained in the fusion (Supplemental Figure S4),
which raises the possibility that the fusion protein can bind its Gβ part-
ner, whether at the cell membrane or in the cytoplasm.
PRKAA1-TTC33. PRKAA1 encodes a 5′-AMP–activated protein
kinase catalytic subunit α-1; TTC33 encodes tetratricopeptide repeat
domain 33. PRKAA1 is a Ser/Thr protein kinase that protects cells from
Figure 3. Cell growth modulation by chimeras. (A) Control (Table S10) and chimera-targeting siRNA are color coded. (Top, left) MCF-7;
PRKAA-TTC33 (cyan), SAMM50-PARVB (green), control (black). (Top, right) HBL-100; CHD2-CHMP1A (orange), control (black). (Bottom,
left) OVCAR-3; URB1-C21ORF45 (blue), CTBS-GNG5 (red). (Bottom, right) HBL-100 treated with siRNA for chimeras from ovarian libraries;
URB1-C21ORF45 (blue), CTBS-GNG5 (red). Bars, SD. Brackets, P value of two-way analysis of variance; Bonferroni t test significance: *P ≤
.05; ***P ≤ .001. (B) Real-time PCR of siRNA-transfected cells. (Top) Chimeric RNA (left to right: PRKAA-TTC33 and SAMM50-PARVB in
MCF-7; URB1-C21ORF45 and CTBS-GNG5 in OVCAR-3). (Bottom) Single-partner RNA expression after the indicated siRNA treatment (left
to right: PRKAA-TTC33 and SAMM50-PARVB in MCF-7). (C) Flow cytometry analysis of transfected HBL-100 and MCF7 cells; YFP was
used as a transfection efficiency benchmark. (Left) HBL-100; LTX (red) or Lipo-2000 (blue). (Right) MCF-7; LTX transfection. (D) MCF-7 cell
growth blockade after PRKAA-TTC33–targeted or SAMM50-PARVB–targeted siRNA treatment (day 6 after transfection).
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stress-dependent ATP depletion by switching off ATP-consuming
biosynthetic pathways; PRKAA1 also regulates fatty acid and choles-
terol synthesis. The N-terminal segment retained in the chimera
contains most of the protein kinase A1 protein (478/559 amino acids;
Table S11). This retains the full catalytic domain (46–279). However,
it loses 12 phosphorylation sites (T488, T490, T522, S496, S502,
S506, S508, S516, S520, S523, S524, and S527), which suggests the
loss of at least some of its physiological regulation. The fusion protein
contains 32 C-terminal amino acids from the 3′ partner mRNA
(TTC33), which do not correspond to its canonical reading frame
(out-of-frame fusion; Table S11).
SAMM50-PARVB. SAMM50 encodes the sorting and assembly
machinery (SAM) component 50 homolog; PARVB encodes β-parvin.
SAM-50 is part of the SAM complex, which has a role in integrating
β-barrel proteins into the outer mitochondrial membrane. β-Parvin
is an actin-binding protein that associates with focal contacts. Parvin
is a key regulator of integrin-linked kinase (ILK) and of its down-
stream pathways. The encoded fusion protein contains an almost
entire SAM-50, which only misses its last 15 C-terminal amino acids
(Table S11). However, this may lead to disruption of the second
major functionally relevant domain of SAM-50. Only two amino
acids are contributed by the β-parvin mRNA, as an out-of-frame
sequence (Table S11).
URB1-C21orf45. URB1 encodes the pre-ribosomal–associated
protein 1 (Npa1p);C21orf45 encodes the kinetochore protein homolog
A. Npa1p is a component of pre-60S ribosomal particles and associates
with small nucleolar ribonucleoprotein particles (RNPs) that are re-
quired for peptidyl transferase center modification. The kinetochore
protein homolog A is involved in mitosis and associates with chroma-
tin. It also associates with centromeres in interphase cells, from late
anaphase to G1. The fusion protein keeps essentially all the exons of
the N-terminal partner (38/39), including its S1385 phosphorylation
site (Table S11), suggesting a largely unaltered function. Albeit the
C-terminal sequence is not in its native frame, it is unusually long
(121 amino acids; Table S11) and may carry novel associated functions.
Chimeras Contain Positive and Negative Regulators of
Cell Growth
The six chimeras that were found to be expressed by target cell
lines in culture were assayed for a role in cell growth. siRNA target-
ing the chimeric joint (Table S11) were used to inhibit the expression
of the corresponding chimeras in breast cancer cells (Figure 3). Trans-
fection efficiency was optimized by using a co-transfected pEYFP
reporter plasmid (Figure 3C , left); the vast majority of target cells
appeared successfully transfected (Figure 3C ). Transfected siRNA
downregulated mRNA chimera levels by ≈75% (Figures 3B and
S3). To ensure absence of off-target effects, due to artifactual reduction
of chimera partner transcript levels, 5′ and 3′ chimeric partners were
analyzed in parallel. Levels of partner transcripts of growth regulatory
chimeras remained unaffected by siRNA targeting the chimera junction
regions (Figure 3B ).
Remarkably, five of six tested chimeras appeared to regulate cell
growth. The strongest growth inhibition in HBL-100 cancer cells
Figure 4. Expression of mRNA chimeras in normal tissues. (A) (Left) Agarose electrophoresis analysis of real-time PCR products (Sybr
Green real-time PCR). (Right) Real-time PCR analysis of the CHD2-CHMP1A chimeric mRNA in normal tissues (PrimeTime real-time
PCR). HBL-100 cell cDNA was used as a positive control. (Bottom) Amplification plots of CHD2-CHMP1A mRNA in the HBL-100 breast
cancer cell line (blue) and normal breast tissue (red). CHD2-CHMP1A (top lanes) and GAPDH (bottom lanes) were amplified in duplicate.
Green triangles, successful amplification; red triangles, no amplification. (B) Agarose electrophoresis of nested PCR products of PRKAA1-
TTC33, SAMM50-PARVB, CTBS-GNG5, and URB1-C21orf45 in normal tissues.
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was caused by down-regulation of CHD2-CHMP1A (Figure 3A ).
Parallel growth blockade in MCF-7 cells was observed on shutdown
of PRKAA-TTC33 and SAMM50-PARVB (Figures 3A and S3B).
Monitoring of cell growth inhibition by PRKAA-TTC33 and
SAMM50-PARVB siRNA through optical microscopy (Figure 3D) and
image analysis (Figure S3, B and C) confirmed a dramatic reduction of
MCF-7 cell growth. Growth inhibition by PRKAA-TTC33 and SAMM50-
PARVB down-regulation was also demonstrated for HBL-100 cells.
We then went on to test URB1-C21ORF45–targeting siRNA in
ovarian cell lines. Unexpectedly, an increase in cell growth was reproduc-
ibly observed in OVCAR-3 (Figure 3A ) and IGROV-1 cells, which
indicates a growth inhibitory role of the URB1-C21ORF45 chimera.
Albeit URB1-C21ORF45 is expressed by SKOV-3 and HBL-100 cells,
the corresponding siRNA had no effects on these cells, suggesting a cell-
specific function of these growth inhibitory chimera (Figure 3A). These
tests were repeated using CTBS-GNG5–targeted siRNA. These assays
showed that theCTBS-GNG5 chimera also has a growth inhibitory func-
tion in OVCAR-3 and IGROV-1 cells (Figures 3 and S3B). Again,
SKOV-3 and HBL-100 cancer cells were insensitive to the inhibitory
function of CTBS-GNG5, consistent with a differential tuning of
chimera-dependent growth-control circuitries in specific cell lines.
Protein-encoding reading frames of the growth regulatory chimeras
were analyzed (Table S11). In all cases but one, the downstream part-
ners did not provide in-frame sequences, generating out-of-frame,
mostly short chimeric tails. This suggested altered regulation and/or
dominant-negative function of a truncated molecule as a mechanism
of action of these chimeric products. However, the CTBS-GNG5 is
an in-frame chimera that retains the first 319 amino acids from the
Figure 5. Expression of mRNA chimeras in primary tumors. (A, B) Agarose electrophoresis analysis of amplification products. Tumor
origin and sample numbers are indicated. (A) Intrachromosomal chimeras as analyzed by real-time PCR. PRKAA1-TTC33 and CTBS-GNG5
were diagnosed in all 25 tumors; SAMM50-PARVB chimeric was found in 15 tumors, P2RX5-TAX1BP3 in 8 tumors, and URB1-C21orf45
in 21 tumors. (B) PCR amplicons of the interchromosomal CHD2-CHMP1A chimera. (C) Interchromosomal ADK-DHX8 chimeric. Melting
temperature and real-time amplification curves.
Table 1. Expression of Chimeric mRNA by Tumor Type.
Chimera Breast* [n/10 (%)] Ovary [n/2 (%)] Stomach [n/2 (%)] Colon [n/7 (%)] Kidney [n/2 (%)] Uterus [n/2 (%)]
PRKAA-TTC33 8 (80) 2 (100) 2 (100) 7 (100) 2 (100) 2 (100)
SAMM50-PARVB 5 (50) – 1 (50) 5 (71) 2 (100) 1 (50)
P2RX5-TAX1BP3 2 (20) – – 5 (71) 1 (50) 1 (50)
URB1-C21ORF45 8 (80) – 1 (100) 7 (100) 2 (100) 2 (100)
CTBS-GNG5 8 (80) 1 (50) 2 (100) 7 (100) 2 (100) 2 (100)
CHD2-CHMP1A 3 (30) – 2 (100) 2 (28) 1 (50) 2 (100)
ADK-DHX8 – – – 1 (14) 1 (50) –
–, Not detected.
*Tumors; total numbers are below each histotype.
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N-terminal chitobiase and most of the C-terminal Gγ5 (41 amino
acids), including its Gβ-binding interface (Figure S2). This sug-
gested that the chimeric protein can bind its Gβ partner in trimeric
G proteins (Supplemental Sequence Data).
Chimera Expression in Normal Tissues
We assessed the presence and expression levels of the five growth-
controlling chimeras in mRNA from normal tissues (breast, lung,
placenta, uterus, prostate, stomach, colon, pancreas, and kidney)
by nested and real-time PCR. The four intrachromosomal chimeras
(PRKAA-TTC33, SAMM50-PARVB, URB1-C21ORF45, and CTBS-
GNG5 ) were detected in all screened normal tissues (Figure 4). This
was consistent with previous findings on the expression of oncogenic
mRNA chimeras in normal tissues [4,13,14,17–20]. However, we
found essentially no trace of the CHD2-CHMP1A interchromosomal
chimera in normal tissues. CHD2-CHMP1A was expressed by almost
all cancer cell lines (13/14), thus appearing as a cancer-related event.
Expression of Growth Regulatory Chimeras in
Primary Tumors
In vitro cell growth regulatory chimeras are expressed by different
cancer histotypes. Total RNAwas extracted frombreast, ovarian, gastric,
colon, kidney, and uterine tumors [13,48], was reverse transcribed, and
amplified. We took advantage of chimeric-band melting-temperature
specificity peaks (Figure S3E) to select for bona fide amplification can-
didates. Amplified candidates were then systematically sequenced.
PRKAA-TTC33 was detected in all 25 of these tumors, SAMM50-
PARVB in 15 tumors, P2RX5-TAX1BP3 in 8 tumors, and URB1-
C21ORF45 in 21 tumors; CTBS-GNG5 was detected in almost all
tumors (Figure 5A and Table 1); CHD2-CHMP1A was identified in
11 tumors (Figure 5B ). ADK-DHX8 was diagnosed in two tumors
(Figure 5C ). Hence, growth regulatory chimeras are broadly expressed
in human tumors but in heterogeneous manners. This suggests a posi-
tive selective pressure [49] for a fusion mRNA-based growth regulatory
mechanism during tumor development, which appears to operate in a
chimera and tumor-type–specific manner.
Discussion
We have opened the field of the in silico identification of mRNA
chimeras in cancer cells, through analysis of cDNA sequence data-
banks [24]. NGS approaches have enormously increased the amount
of sequencing data of potential use for chimera discovery. However,
short-read second-generation NGS analyses identify mRNA chimeras
through a probabilistic fitting of highly multiplexed short-tag data
sets [7,19,20,25–28,50–53], which severely affects both specificity
and sensitivity of detection of mRNA chimeras. However, rapid
progress is being made toward achieving longer sequence reads and
higher sequencing accuracy, which allows to reduce sequence errors
while improving contig assembly procedures. To permit high-
throughput, high-specificity chimera discovery in long-read sequence
data sets, we have developed the FusionMiner search strategy. This
was shown to reach a 95.9% chimera identification specificity, with a
low 4.1% false-negative classification rate. This search strategy was
extensively validated by RT-PCR and cDNA sequencing (Table S1b).
Global chimera frequencies were computed for separate sequenc-
ing projects. Analysis of a human transcriptomic 454 data set of
19,527 contigs and 173,005 singletons led to the identification
of four sequences as bona fide chimeras, for a chimera frequency of
4/192,532, i.e., 2 × 10−5 of all mRNA. High-throughput sequencing
of cDNA libraries from tumors and corresponding normal tissues
generated 1,774,453 long-read sequences. Twenty-five were identi-
fied by FusionMiner as bona fide chimeras, for a chimera frequency
of 25/1,774,453, i.e., 1.4 × 10−5, in remarkable agreement with the
NGS data. Taken together, these findings suggest a chimera fre-
quency of ≈2 × 10−5 in cellular transcriptomes. Issues of data set
size and of transcriptome tissue specificity suggest these to be mini-
mal estimates. A proof of principle of this scenario was obtained, as
one of the interchromosomal chimeras, which could not be detected
in cell lines, and was identified in 2 of 10 primary breast cancers.
Most of the chimeras analyzed were shown to have a regulatory role
in transformed cell growth [54,55]. Notably, tumor growth inhibitory
mRNA chimeras, e.g.,URB1-C21ORF45 and CTBS-GNG5, were also
discovered. Of interest, these were shown to have inhibitory capacity
on the growth of a subset of ovarian cancer cells, whereas other ovarian
and breast cancer cells were not affected, suggesting different regula-
tory contexts for chimera-driven growth control in different cell lines.
Most tumors were shown to express these growth regulatory chimeras,
consistent with a positive selective pressure for exploiting this growth
regulatory mechanism during tumor development.
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2Supplemental Material and Methods
Chimeric mRNA detection procedure. We designed the FusionMiner software workflow (Figure 1) 
to process BLAST analyses of query sequences against genomic databanks via sequential stages of
analysis and exclusion, pass-or-fail tests. Candidate chimera were cross-validated versus
experimentally verified sequences and by RT-PCR.
Alignments versus genomic assemblies were first parsed to remove spurious data on the basis of 
length and percent identity (=98%, over =95% of a candidate length). Individual filtered alignments
were then clustered and concatenated across alignment breaks and intronic regions, based on a
permissible gap criterion, to identify their genomic context. Sequences aligning to one or two
chromosomes were segregated and processed separately, as intra-chromosomal (which most frequently
derive from inter-genic transcription) and inter-chromosomal (which most frequently derive from
chromosomal translocations and trans-splicing) chimeric candidates, respectively.
The fusion point (FP) for inter-chromosomal candidates was expected to correspond to the point 
in a clustered alignment where a sequence ceased to align with one chromosome and started to align
with the second. Alignments on either side of a FP were assessed on the basis of length and percent 
identity (defaults =100 bp length, =98% identity), following clustering of the original alignments and
weighted averaging of percent identities. This was to ensure that only high-quality alignment data were
used in chimeras detection, while low quality or spurious alignments were dropped out. FPs were then 
examined and filtered, based on the degree of overlap at this position (default =10 bp). Allowing this 
degree of error ensured retention of true chimeras with small areas of fortuitous sequence homology
across the other side of the FP. A parallel filtration procedure was applied for gaps at FP (default =10
bp), which allowed to compensate for possible sequencing errors at this position. Successful candidates 
were then checked for agreement of their FP with known exon boundaries, using genomic coordinate
data from Ensembl, although non-canonical FP (i.e. recombinations within exons) were also identified
and separately stored. Ensembl was chosen as genomic coordinate reference site as it contains
confirmed gene predictions, which are integrated with external data sources, including the Sanger
Institute HAVANA [1], RefSeq at NCBI [2], and the UCSC Genome Browser [3]. When candidate-
chimera FPs were found to correspond to an exon-exon boundary, candidates were accepted. Intra-
chromosomal candidates were treated in a corresponding manner. A permissible error threshold
(default 3 bp) was applied at this stage, to compensate for sequencing errors or alignment blurring due 
to small areas of local homology on either side of a boundary.
3Both chimera partner mRNAs were selected for occurrence in the same reading orientation
versus known mRNAs (i.e. plus orientation). Joining to a ‘minus’ strand is, indeed, most likely
generated by cDNA recombination during library construction [4]. A special case is that of a gene that 
transcribes both the minus and the plus strands. Of note, both mRNA classes would be available for
matching in transcript datasets. FusionMiner would then operationally qualify both mRNAs as ‘plus’. 
Accepted candidates then entered a clustering step, whereby they were assessed and grouped if
they shared the same FP. A disagreement of up to 10 bp was allowed during clustering, consistent with 
the errors permitted at the stage of FP definition. Chimeras were then sorted and presented in order of 
multiplicity of occurrence. 
FusionMiner also allowed to identify and cluster candidates which were rejected during the
exon-boundary checking stage. This was to permit the discovery of recurrent, non-canonical chimeras, 
which are expected to derive from DNA joining at recombination hot spots [5].
Prediction of reading-frame preservation at the FP was then performed. 
FusionMiner search performance. The performance of the FusionMiner detection strategy (Figure
S1) was assessed by screening the Dana Farber Cancer Institute (DFCI) Gene Index Project tentative 
human consensus (THC) collection (Figure S1). This led to the identification of 228 chimeras (105
inter-chromosomal and 123 intra-chromosomal), involving 414 genes (Tables S1-S3). Chimeras
discovered by FusionMiner in the DFCI Gene Index Project encoded enzymes (16%), transcription
factors/ chromatin modulators (11.5%), G proteins (5.8%), protein binding partners (5.8%),
transporters (4.5%), cytoskeletal proteins (2.6%), receptors and proteases (1.9%). Curated sequence
analysis [4] indicated that 221 of the 228 chimeric mRNAs candidates (96.9%) did fit all bona fide 
chimera criteria. Sixty-one of these chimeras were uniquely identified by FusionMiner (Table S3).
FusionMiner default settings were optimized to obtain maximum specificity in chimera
detection. To provide differential estimates of performance (sensitivity versus specificity), FusionMiner
analysis parameters were then systematically altered, and their impact on analysis outcomes was
assessed.
Splicing at exon/exon borders: exon-exon boundary settings were relaxed, by extending the tolerance 
up to 8 bp, i.e. exon boundaries were allowed to be identified within 8 bp of BLAST alignments
borders. This can be useful for specific requirements, e.g. for short-sequence-length datasets, or for
alignments to poor-quality genome sequence regions. Thirty-nine additional sequences were obtained
as compared with the default 3 bp tolerance (Tables S1b, S4-S6). Thirty-seven of these appeared to be 
4bona fide chimeras (96.6% specificity, versus 96.9% with optimal/ default parameters, -0.3%
specificity; 228 + 39 = 267; +17.1% sensitivity).
Bp gap: Extending the allowed gaps in FusionMiner to 30 bp, instead of the 10 bp default, resulted in 
identification of only 4 additional chimeras (Tables S1b, S4-S6). Three of these (75%) were bona fide
fusion sequences. 
Percent query identity (%ID): A low %ID might be due to gaps, bad sequencing, or real mismatch
regions. The default requirement for 98% ID was thus relaxed to 94%, to allow detection of these
problematic sequences. Thirty-four additional chimeras were detected versus default values (Tables
S1b, S4-S6). Thirty two of these (91.4%) were confirmed to be true positive bona fide fusion sequences 
(-0.4% specificity; +14.9% sensitivity).
Query length: The FusionMiner strategy/ sequential validation/ parameter combination was optimized
for the recognition of small, bona fide chimeric sequences from NGS analysis. We validated this by
analyzing chimeras with 50-base matches around a fusion joint. By shortening the minimum allowed
length for matches from 100 bp to 50 bp, we identified 59 additional THC sequences versus the default 
searches (Tables S1b, S4-S6). Strikingly, 56 out of these 59 (94.9%) were true positives (-0.4%
specificity; +25.9% sensitivity). Remarkably, 349 of 364 (95.9%) chimeric mRNAs detected by
FusionMiner from THC were shown to fit chimera identification criteria. 
Validation of discovered THC chimeras. THC chimeras from breast cancer (4 sequences) were
searched for in breast cancer cell lines (Figure S1). cDNAs were obtained from MCF-7, MCF-7/Almac,
HBL-100, SK-BR-3, MDA-MB-231, MDA-MB-361, MDA-MB-415, MDA-MB-453, and MDA-MB-
468 cells, and each chimera was amplified by direct or nested PCR. All PCR amplified bands were 
verified by sequencing. Successful amplification was achieved for 3 out of 4 chimeras (75%), i.e.
THC2538403 ZNF498-CUX1 (4/9 lines), THC2523555 (an additional long intergenic transcript was
identified as ENST00000358157) C9orf47-S1PR3 (8/9 lines) and THC2668182 KLH22-SCARF2 (7/9
lines) (Figure S1). We then extended this analysis to SKOV-3, IGROV-1, OVCAR-3 and OVCA-432
ovarian cancer cells. Two of the chimeras from breast cancer, i.e. THC2523555 C9orf47-S1PR3 and 
THC2668182 KLH22-SCARF2, were identified in all four ovarian cancer cell lines (Figure S1),
suggesting broad expression across different tumor histotypes. Chimeric sequence abundance was
measured by real-time quantitative PCR (Figure S1B). Chimeras were detected at considerably
different levels in the tested cell lines, consistent with a regulated expression [6-11].
5FusionMiner performance on long-reads NGS datasets. FusionMiner was further validated on long-
sequence read from 454-generated output files. A 454 Titanium dataset of 1,241,098 reads, 355.5 bp in 
average length (www.bmr-genomics.it/~alex/ALBERTI/) was compiled by Newbler into 19,527 
contigs and 173,005 singletons; 28,561 sequences were identified as outliers. FusionMiner identified 
one inter-chromosomal and three intra-chromosomal bona fide chimeras (Tables S1, S7, Supplemental
Sequence Data). These findings reveal absolute chimeras frequencies of 2x10-5 (4 out of 192,532) in 
whole cell transcriptomes.submis
6Supplemental Sequence Data
Sequences, BLAST alignments, and exons involved in fusions are indicated for the individual 
novel chimeras identified from specific sequencing datasets. The interaction networks of the 
proteins encoded by growth-regulatory chimera partners are shown. 
Legend:
Borders of exons involved at junction points are indicated before each BLAST alignment.
Arrows indicate beginning/ end of BLAST alignments.
Chromosome location of each partner gene is indicated.















Sanger sequencing (forward and reverse)
EMBOSS_001      1 TTTGCGTGTACGAAGGAAGAATCCTGTGACAAGCACTTACTCCAAAATGA     50
                     ||||||||||||||||||||||||||||||||||||||||||||||||||
Pcr band   1 TTTGCGTGTACGAAGGAAGAATCCTGTGACAAGCACTTACTCCAAAATGA  50
EMBOSS_001     51 GTCTACAGTTATACCAAGTGGATAGTAGAACTTATCTACTGGATTTCCGT    100
                     ||||||||||||||||||||||||||||||||||||||||||||||||||
Pcr band 51 GTCTACAGTTATACCAAGTGGATAGTAGAACTTATCTACTGGATTTCCGT 100
EMBOSS_001    101 AGTATTGATGAATGGCTTCCTTTGGGTGGAAGAGGAAAATTGGTGAGAAG   150
                     ||||||||||||||||||||||||||||||||||||||||||||||||||
Pcr band     101 AGTATTGATGAATGGCTTCCTTTGGGTGGAAGAGGAAAATTGGTGAGAAG 150
EMBOSS_001    151 GTCTCAAAGGTCACTTCCCAGC    172
      ||||||||||||||||||||||






/gene_synonym="AMPK; AMPKa1; MGC33776; MGC57364"
BLAST vs mRNA
>ref|NM_006251.5| UniGene info linked to NM_006251.5GEO profiles info linked to NM_006251.5Gene info 
linked to NM_006251.5Genome view with mapviewer linked to NM_006251.5 Homo sapiens protein kinase, AMP-
activated, alpha 1 catalytic subunit (PRKAA1), transcript variant 1, mRNA
Length=5085
GENE ID: 5562 PRKAA1 | protein kinase, AMP-activated, alpha 1 catalytic subunit [Homo sapiens]
Score = 1162 bits (629),  Expect = 0.0
Identities = 629/629 (100%), Gaps = 0/629 (0%)
Strand=Plus/Plus
Query  5     ATCAAAGATATCAGGGAACATGAATGGTTTAAACAGGACCTTCCAAAATATCTCTTTCCT  64
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  814   ATCAAAGATATCAGGGAACATGAATGGTTTAAACAGGACCTTCCAAAATATCTCTTTCCT  873
Query  65    GAGGATCCATCATATAGTTCAACCATGATTGATGATGAAGCCTTAAAAGAAGTATGTGAA  124
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  874   GAGGATCCATCATATAGTTCAACCATGATTGATGATGAAGCCTTAAAAGAAGTATGTGAA  933
Query  125   AAGTTTGAGTGCTCAGAAGAGGAAGTTCTCAGCTGTCTTTACAACAGAAATCACCAGGAT  184
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  934   AAGTTTGAGTGCTCAGAAGAGGAAGTTCTCAGCTGTCTTTACAACAGAAATCACCAGGAT  993
Query  185   CCTTTGGCAGTTGCCTACCATCTCATAATAGATAACAGGAGAATAATGAATGAAGCCAAA  244
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 994   CCTTTGGCAGTTGCCTACCATCTCATAATAGATAACAGGAGAATAATGAATGAAGCCAAA  1053
Query  245   GATTTCTATTTGGCGACAAGCCCACCTGATTCTTTTCTTGATGATCATCACCTGACTCGG  304
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1054  GATTTCTATTTGGCGACAAGCCCACCTGATTCTTTTCTTGATGATCATCACCTGACTCGG  1113
Query  305   CCCCATCCTGAAAGAGTACCATTCTTGGTTGCTGAAACACCAAGGGCACGCCATACCCTT  364
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1114  CCCCATCCTGAAAGAGTACCATTCTTGGTTGCTGAAACACCAAGGGCACGCCATACCCTT  1173
Query  365   GATGAATTAAATCCACAGAAATCCAAACACCAAGGTGTAAGGAAAGCAAAATGGCATTTA  424
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1174  GATGAATTAAATCCACAGAAATCCAAACACCAAGGTGTAAGGAAAGCAAAATGGCATTTA  1233
Query  425   GGAATTAGAAGTCAAAGTCGACCAAATGATATTATGGCAGAAGTATGTAGAGCAATCAAA  484
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1234  GGAATTAGAAGTCAAAGTCGACCAAATGATATTATGGCAGAAGTATGTAGAGCAATCAAA  1293
Query  485   CAATTGGATTATGAATGGAAGGTTGTAAACCCATATTATTTGCGTGTACGAAGGAAGAAT  544
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1294  CAATTGGATTATGAATGGAAGGTTGTAAACCCATATTATTTGCGTGTACGAAGGAAGAAT  1353
Query  545   CCTGTGACAAGCACTTACTCCAAAATGAGTCTACAGTTATACCAAGTGGATAGTAGAACT  604
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1354  CCTGTGACAAGCACTTACTCCAAAATGAGTCTACAGTTATACCAAGTGGATAGTAGAACT  1413
Query  605   TATCTACTGGATTTCCGTAGTATTGATGA  633
   |||||||||||||||||||||||||||||
Sbjct  1414  TATCTACTGGATTTCCGTAGTATTGATGA  1442
Ï 
Summary for PRKAA1
PKA belongs to Ser/Thr protein kinases. It is the 
catalytic subunit of the cAMP-activated protein
kinase (AMPK). AMPK is a cellular energy sensor 
conserved in all eukaryotic cells. The kinase activity
of AMPK is activated by the stimuli that increase cell 
AMP/ATP ratio. AMPK regulates key metabolic
enzymes through phosphorylation. It protects cells 
from stress that causes ATP depletion by switching-
off ATP-consuming biosynthetic pathways. PKA 
regulates fatty acid synthesis by phosphorylation of
acetyl-CoA carboxylase. It also regulates cholesterol 












>ref|NM_012382.2| UniGene info linked to NM_012382.2GEO profiles info linked to NM_012382.2Gene info 
linked to NM_012382.2Genome view with mapviewer linked to NM_012382.2 Homo sapiens tetratricopeptide 
repeat domain 33 (TTC33), mRNA
Length=5519
GENE ID: 23548 TTC33 | tetratricopeptide repeat domain 33 [Homo sapiens]
Score =  741 bits (401),  Expect = 0.0
Identities = 492/530 (93%), Gaps = 30/530 (5%)
Strand=Plus/Plus
Ð 
Query  632   GAATGGCTTCCTTTGGGTGGAAGAGGAAAATTGGTGAGAAGGTCTCAAAGGTCACTTCCC  691
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  147   GAATGGCTTCCTTTGGGTGGAAGAGGAAAATTGGTGAGAAGGTCTCAAAGGTCACTTCCC  206
Query  692  AGCAGTTTGAAGCTGAAGCTGCTGATGAGAAGGATGTAGTTGACAACGATGAA-AGAACT  750
             |||||||||||||||||||||||||||||||||||||||||||||||||||||  |||||
Sbjct  207   AGCAGTTTGAAGCTGAAGCTGCTGATGAGAAGGATGTAGTTGACAACGATGAAGGGAACT  266
Query  751   GGCTTCATGCCATTAAACGTA-GAAAGAAATTCTTCTTGAACGCTGTGCTGAGAAAAGTA  809
             ||||||||||||||||||||| ||||||||||||||||||| ||||||||||||||||||
Sbjct  267   GGCTTCATGCCATTAAACGTAGGAAAGAAATTCTTCTTGAAGGCTGTGCTGAGAAAAGTA  326
Query  810   AACAGCTGAA-GATGAA-GAGCCAGTTTGGCTGAAAATAAAAGATATCGGGAGGCAATTC  867
             |||||||||| |||||| ||||||||||||||||||||||||||||||||||||||||||
Sbjct  327   AACAGCTGAAGGATGAAGGAGCCAGTTTGGCTGAAAATAAAAGATATCGGGAGGCAATTC  386
Query  868   AGAAGTGGGATGAAGCACTACAGTTAACTCTAAATGATGCTACCCTATACGAGATGAAAT  927
           |||||||||||||||||||||||||||||| |||||||||||||||||||||||||||||
Sbjct  387   AGAAGTGGGATGAAGCACTACAGTTAACTCCAAATGATGCTACCCTATACGAGATGAAAT  446
Query  928   CACAG-TGCTAATGTCTCTTCATGAAATGTTCCCAGCAGTACATGCAGCAGAAATG-CCG  985
             ||||| |||||||||||||||||||||||||||||||||||||||||||||||||| |||
Sbjct  447   CACAGGTGCTAATGTCTCTTCATGAAATGTTCCCAGCAGTACATGCAGCAGAAATGGCCG  506
TTC33 interaction network.
Summary for TTC33
Tetratricopeptide repeat protein 33. Size: 262 















Sanger sequencing (forward and reverse)
RDBC0852_G11.   2 TCGCTCGGTTGGAACTTAATTACTGCGTCCCCATGGGAGTACAGACAGGT  51
                     |||||||||||||||||||||||||||||||||||||||||||||||||.
FUSintra3-4R2      2 TCGCTCGGTTGGAACTTAATTACTGCGTCCCCATGGGAGTACAGACAGGC     51
RDBC0852_G11.    620 GACAGTGAGTGACCTGCAGGAAGAAGGCAAGAATGCCATCAACTCACCG  101
                     |||||||||||||||||||||||||||||||||||||||||||||||||





/gene_synonym="CGI-51; FLJ35825; FLJ42905; FLJ99036;
OMP85; SAM50; TOB55; TRG-3; YNL026W"
BLAST vs mRNA
>ref|NM_015380.4| UniGene info linked to NM_015380.4GEO profiles info linked to NM_015380.4Gene info 
linked to NM_015380.4Genome view with mapviewer linked to NM_015380.4 Homo sapiens sorting and assembly 
machinery component 50 homolog (S. cerevisiae) (SAMM50), mRNA
Length=1773
GENE ID: 25813 SAMM50 | sorting and assembly machinery component 50 homolog (S. cerevisiae) [Homo 
sapiens]
Score = 1129 bits (611),  Expect = 0.0
Identities = 617/620 (99%), Gaps = 0/620 (0%)
Strand=Plus/Plus
Query  5     GAAAGCGGACATTCACTGAAATCATCTCTTTCGCACGCCATGGTCATCGATTCTCGGAAT  64
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  942   GAAAGCGGACATTCACTGAAATCATCTCTTTCGCACGCCATGGTCATCGATTCTCGGAAT  1001
Query  65    TCTTCCATCTTACCAAGGAGAGGTGCTTTGCTGAAAGTTAACCAGGAACTGGCAGGCTAC  124
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1002  TCTTCCATCTTACCAAGGAGAGGTGCTTTGCTGAAAGTTAACCAGGAACTGGCAGGCTAC  1061
Query  125   ACTGGCGGGGATGTGAGCTTCATCAAAGAAGATTTTGAACTTCAGTTGAACAAGCAACTC  184
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1062  ACTGGCGGGGATGTGAGCTTCATCAAAGAAGATTTTGAACTTCAGTTGAACAAGCAACTC  1121
Query  185   ATATTTGATTCAGTTTTTTCAGCGTCTTTCTGGGGCGGAATGTTGGTACCCATTGGTGAT  244
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1122  ATATTTGATTCAGTTTTTTCAGCGTCTTTCTGGGGCGGAATGTTGGTACCCATTGGTGAT  1181
Query  245   AAGCCGTCAAGCATTGCTGATAGGTTTTACCTCGGGGGACCCACAAGCGTCCGCGGATTC  304
             |||||||||||||||||||||||||||||||| ||||||||||||||| |||||||||||
Sbjct  1182  AAGCCGTCAAGCATTGCTGATAGGTTTTACCTTGGGGGACCCACAAGCATCCGCGGATTC  1241
10
Query  305   AGCATGCACAGCATCGGGCCACAGAGCGAAGGAGACTACCTAGGTGGAGAAGCGTACTGG  364
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1242  AGCATGCACAGCATCGGGCCACAGAGCGAAGGAGACTACCTAGGTGGAGAAGCGTACTGG  1301
Query  365   GCCGGCGGCCTGCACCTCTACACCCCATTACCTTTCCGGCCAGGCCAGGGTGGCTTTGGA  424
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1302  GCCGGCGGCCTGCACCTCTACACCCCATTACCTTTCCGGCCAGGCCAGGGTGGCTTTGGA  1361
Query  425   GAACTTTTCCGAACACACTTCTTTCTCAACGCAGGAAACCTCTGCAACCTCAACTATGGG  484
      ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1362  GAACTTTTCCGAACACACTTCTTTCTCAACGCAGGAAACCTCTGCAACCTCAACTATGGG  1421
Query  485   GAGGGCCCCAAAGCTCATATTCGTAAGCTGGCTGAGTGCATCCGCTGGTCGTACGGGGCC  544
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1422  GAGGGCCCCAAAGCTCATATTCGTAAGCTGGCTGAGTGCATCCGCTGGTCGTACGGGGCC  1481
Query  545   GGGATTGTCCTCAGGCTTGGCAACATCGCTCGGTTGGAACTTAATTACTGCGTCCCCATG  604
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1482  GGGATTGTCCTCAGGCTTGGCAACATCGCTCGGTTGGAACTTAATTACTGCGTCCCCATG  1541
Query  605   GGAGTACAGACAGGTGACAG  624
             |||||||||||||| |||||









>ref|NM_001003828.1| UniGene info linked to NM_001003828.1GEO profiles info linked to 
NM_001003828.1Gene info linked to NM_001003828.1Genome view with mapviewer linked to NM_001003828.1 
Homo sapiens parvin, beta (PARVB), transcript variant 1, mRNA
Length=1808
GENE ID: 29780 PARVB | parvin, beta [Homo sapiens]
Score =  684 bits (370),  Expect = 0.0
Identities = 471/514 (92%), Gaps = 30/514 (5%)
Strand=Plus/Plus
Ð 
Query  623   AGTGAGTGACCTGCAGGAAGAAGGCAAGAATGCCATCAACTCACCGATGTCCCCCGCCCT  682
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  258   AGTGAGTGACCTGCAGGAAGAAGGCAAGAATGCCATCAACTCACCGATGTCCCCCGCCCT  317
Query  683   GGCGGATGTTCACCCTGAAGACACCCAGCTCGAGGAGAACGAGGAGCGCACGATGATTGA  742
             || ||||||||||||||||||||||||||| |||||||||||||||||||||||||||||
Sbjct  318   GGTGGATGTTCACCCTGAAGACACCCAGCTTGAGGAGAACGAGGAGCGCACGATGATTGA  377
Summary for SAMM50
SAMM50 is a component of the sorting 
and assembly machinery (SAM) complex 
of the outer mitochondrial membrane. The 
SAM complex has a role in integrating 
beta-barrel proteins into the outer
mitochondrial membrane.
11
Query  743   CCCCACTTCC-ACGAAGACCCCAAGTTCAAGGAACTGGTCAAGGTCCTCCTCGACTGGAT  801
             |||||||||| | |||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  378   CCCCACTTCCAAGGAAGACCCCAAGTTCAAGGAACTGGTCAAGGTCCTCCTCGACTGGAT  437
Query  802   TAATGACGTGCTGGTGGAGGAGAGGATCATTGTGAAGCAGCTGGAGGAAGACCTGTATGA  861
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  438   TAATGACGTGCTGGTGGAGGAGAGGATCATTGTGAAGCAGCTGGAGGAAGACCTGTATGA  497
Query  862   CGGCCAGGTGCTGCAGAATCTCTTGGAAAAACTGGCAAGGTGCAAGCTGAATGTGGCTGA  921
  |||||||||||||||||| |||||||||||||||||| ||||||||||||||||||||||









Sanger sequencing (forward and reverse)
EMBOSS_001         1 GCCCTCTCCCTGTCTTCTCTGAGTGAGAAGGATGAAGCCACACAAGGTGT     50
                     ||||||||||||||||||||||||||||||||||||||||||||||||||
PCR band       1 GCCCTCTCCCTGTCTTCTCTGAGTGAGAAGGATGAAGCCACACAAGGTGT 50
EMBOSS_001        51 TTCCTGTAATGTTTCTGTGGATAAGGAACAGAAGCTATCCAAACGTGAAA    100
                     ||||||| ||||||||||||||||||||||||||||||||||||||||||
PCR band         21 TTCCTGT-ATGTTTCTGTGGATAAGGAACAGAAGCTATCCAAACGTGAAA    100
EMBOSS_001       101 AGGAAAATGGTTGCGTCCTTGAG-    123
                     ||||||||||||||||||||||| 
PCR band 101 AGGAAAATGGTTGCGTCCTTGAGA 123
5’ partner: URB1
PARVB interaction network.
Beta parvin is involved in integrin linked kinase signaling. It directly 
interacts with ILK, ACTIN, ALPHA ACTININ and other proteins.
Summary for PARVB
Members of the parvin family,
including PARVB, are actin-binding
proteins associated with focal
contacts. It probably has a role in the 








>ref|NM_014825.2| UniGene info linked to NM_014825.2GEO profiles info linked to NM_014825.2Gene info 
linked to NM_014825.2Genome view with mapviewer linked to NM_014825.2Download subject sequence 
NM_014825 spanning the HSP Homo sapiens URB1 ribosome biogenesis 1 homolog (S. cerevisiae) 
(URB1), mRNA
Length=10808
GENE ID: 9875 URB1 | URB1 ribosome biogenesis 1 homolog (S. cerevisiae) [Homo sapiens]
Score =  322 bits (174),  Expect = 7e-87
Identities = 176/177 (99%), Gaps = 0/177 (0%)
Strand=Plus/Plus
Query  1     ATAGCCGGCTCTGTGGGGCTGAGGGGCTGGCAGGGCCTGTGCAGGAGGTGGCCTGCCTGT  60
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  6551  ATAGCCGGCTCTGTGGGGCTGAGGGGCTGGCAGGGCCTGTGCAGGAGGTGGCCTGCCTGT  6610
Query  61    TCAATACGGTCATGCTGCAGCTGGTGGCTGCCCAGGGCCGGGCAGGGAGCCCTTTCCACC  120
             |||||||||||||||||||||||||||||||||||||||||||||||||||| |||||||
Sbjct  6611  TCAATACGGTCATGCTGCAGCTGGTGGCTGCCCAGGGCCGGGCAGGGAGCCCCTTCCACC  6670
Query  121   CGGCCATGGAAGCCCTCTCCCTGTCTTCTCTGAGTGAGAAGGATGAAGCCACACAAG  177
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||







/gene_synonym="B28; C21orf45; C21orf46; FASP1; hMis18alpha; MIS18alpha"
BLAST vs mRNA
>ref|NM_018944.2| UniGene info linked to NM_018944.2GEO profiles info linked to NM_018944.2Gene info 
linked to NM_018944.2Genome view with mapviewer linked to NM_018944.2 Homo sapiens MIS18 kinetochore 
protein homolog A (S. pombe) (MIS18A), mRNA
Length=1587
GENE ID: 54069 MIS18A | MIS18 kinetochore protein homolog A (S. pombe) [Homo sapiens]
Score =  826 bits (447),  Expect = 0.0
Identities = 451/453 (99%), Gaps = 0/453 (0%)
Summary for URB1
Nucleolar pre-ribosomal-associated protein 1.





Query  178  GTGTTTCCTGTAATGTTTCTGTGGATAAGGAACAGAAGCTATCCAAACGTGAAAAGGAAA  237
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  386  GTGTTTCCTGTAATGTTTCTGTGGATAAGGAACAGAAGCTATCCAAACGTGAAAAGGAAA  445
Query  238  ATGGTTGCGTCCTTGAGACTTTGTGCTGCGCGGGGTGCTCACTCAATCTTGGCTACGTGT  297
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  446  ATGGTTGCGTCCTTGAGACTTTGTGCTGCGCGGGGTGCTCACTCAATCTTGGCTACGTGT  505
Query  298  ACAGATGCACGCCCAAGAATCTTGATTACAAGAGAGACTTGTTTTGCCTCAGTGTTGAAG  357
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  506  ACAGATGCACGCCCAAGAATCTTGATTACAAGAGAGACTTGTTTTGCCTCAGTGTTGAAG  565
Query  358  CCATTGAAAGTTATGTTTTAGGGTCCTCTGAAAAGCAAATTGTGTCAGAAGATAAAGAGC  417
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  566  CCATTGAAAGTTATGTTTTAGGGTCCTCTGAAAAGCAAATTGTGTCAGAAGATAAAGAGC  625
Query  418  TTTTTAATCTTGAAAGCAGAGTTGAAATAGAAAAGTTTCTAACACAGATGGAAGATGTCT  477
            |||||||||||||||||||||||||||||||||||| |||||||||||||||||||||||
Sbjct  626  TTTTTAATCTTGAAAGCAGAGTTGAAATAGAAAAGTCTCTAACACAGATGGAAGATGTCT  685
Query  478  TGAAAGCATTACAAATGAAGCTGTGGGAGGCCGAATCCAAATTGTCCTTTCCCACTTGTA  537
            |||||||||||||||||||||||||||||||||||||||||||||||||| |||||||||
Sbjct  686  TGAAAGCATTACAAATGAAGCTGTGGGAGGCCGAATCCAAATTGTCCTTTGCCACTTGTA  745
Query 538  AAAGCTGAACTCTAGTCTGTGTCCTCCATTCTGCCCCCGCCCTTCCTCCCCTTATTTGTT  597
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  746  AAAGCTGAACTCTAGTCTGTGTCCTCCATTCTGCCCCCGCCCTTCCTCCCCTTATTTGTT  805
Query  598  AAATGAAGCAACATAGTGAGACGTCGTCTCTAC  630
            |||||||||||||||||||||||||||||||||
Sbjct  806  AAATGAAGCAACATAGTGAGACGTCGTCTCTAC  838
C21ORF45 interaction network.








Sanger sequencing (forward and reverse)
EMBOSS_001         1 -CCTACAAAACGATCATGAAGCAAATAAATAGTTCTATTTCTGGAAACCT     49
                      |||||||||||||||||||||||||||||||||||||||||||||||||
PCR band           1 TCCTACAAAACGATCATGAAGCAAATAAATAGTTCTATTTCTGGAAACCT     50
EMBOSS_001        50 ATGGGATAAAGATCAGCGGGCTCCTTATTATAACTATAAAGTTTCCCAGG     99
                     ||||||||||||||||||||||||||||||||||||||||||||||||||
PCR band 51 ATGGGATAAAGATCAGCGGGCTCCTTATTATAACTATAAAGTTTCCCAGG   100
EMBOSS_001       100 CAGCTGCAGACTTGAAACAGTTCTGTCTGCAGAATGCTCAACATGACC    147
                     ||||||||||||||||||||||||||||||||||||||||||||||||
PCR band         101 CAGCTGCAGACTTGAAACAGTTCTGTCTGCAGAATGCTCAACATGACC 148
Summary for C21ORF45
MS18A_HUMAN, Q9NYP9. Protein Mis18-alpha. Subunit: 
Homodimer, and heterodimer with MIS18B. Identified in a 
complex containing MIS18A, MIS18B, MIS18BP1, RBBP7
and RBBP4. Subcellular location: nucleus. It associates with
centromeres in interphase cells, from late anaphase to G1 
phase. It is not detected on centromeres during earlier 








>ref|NM_004388.2| UniGene info linked to NM_004388.2GEO profiles info linked to NM_004388.2Gene info 
linked to NM_004388.2Genome view with mapviewer linked to NM_004388.2 Homo sapiens chitobiase, di-N-
acetyl- (CTBS), mRNA
Length=3152
GENE ID: 1486 CTBS | chitobiase, di-N-acetyl- [Homo sapiens]
Score =  327 bits (177),  Expect = 1e-88
Identities = 177/177 (100%), Gaps = 0/177 (0%)
Strand=Plus/Plus
Query  1     TGAATCTGTCTGAGGATCATGTTTGTACCATTGCAAAAGTCCCTTTCCGGGGGGCTCCTT  60
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  847   TGAATCTGTCTGAGGATCATGTTTGTACCATTGCAAAAGTCCCTTTCCGGGGGGCTCCTT  906
Query  61    GTAGTGACGCTGCAGGACGTCAGGTGCCCTACAAAACGATCATGAAGCAAATAAATAGTT  120
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  907   GTAGTGACGCTGCAGGACGTCAGGTGCCCTACAAAACGATCATGAAGCAAATAAATAGTT  966
Query  121   CTATTTCTGGAAACCTATGGGATAAAGATCAGCGGGCTCCTTATTATAACTATAAAG  177
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||









>ref|NM_005274.2| UniGene info linked to NM_005274.2GEO profiles info linked to NM_005274.2Gene info 
linked to NM_005274.2Genome view with mapviewer linked to NM_005274.2 Homo sapiens guanine nucleotide 
binding protein (G protein), gamma 5 (GNG5), mRNA
Length=823
Summary for CTBS
Chitobiase is a lysosomal glycosidase
involved in degradation of asparagine-
linked oligosaccharides on glycoproteins. It 
is also involved on hydrolyzation of N-
acetyl-beta-D-glucosamine (1-4)N-
acetylglucosamine chitobiose from the
reducing end of the bond. This requires 
prior cleavage by glycosyl-asparaginase.
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GENE ID: 2787 GNG5 | guanine nucleotide binding protein (G protein), gamma 5 [Homo sapiens]
Score =  682 bits (369),  Expect = 0.0
Identities = 371/372 (99%), Gaps = 0/372 (0%)
Strand=Plus/Plus
Ð 
Query  174  AAAGTTTCCCAGGCAGCTGCAGACTTGAAACAGTTCTGTCTGCAGAATGCTCAACATGAC  233
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  433  AAAGTTTCCCAGGCAGCTGCAGACTTGAAACAGTTCTGTCTGCAGAATGCTCAACATGAC  492
Query  234  CCTCTGCTGACTGGAGTATCTTCAAGTACAAATCCCTTCAGACCCCAGAAAGTCTGTTCC  293
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  493  CCTCTGCTGACTGGAGTATCTTCAAGTACAAATCCCTTCAGACCCCAGAAAGTCTGTTCC  552
Query  294  TTTTTGTAGTAAAATGAATCTTTCAAAGGTTTCCCAAACCACTCCTTATGATCCAGTGAA  353
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  553  TTTTTGTAGTAAAATGAATCTTTCAAAGGTTTCCCAAACCACTCCTTATGATCCAGTGAA  612
Query  354  TATTCAAGAGAGCTACATTTGAAGCCTGTACAAAAGCTTATCCCTGTAACACATGTGCCA  413
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  613  TATTCAAGAGAGCTACATTTGAAGCCTGTACAAAAGCTTATCCCTGTAACACATGTGCCA  672
Query  414  TAATATACAAACTTTTACTTTCGTCAGTCCTTAACATCTACCTCTCTGAATTTTCATGAA  473
            |||||||||||||| |||||||||||||||||||||||||||||||||||||||||||||
Sbjct  673  TAATATACAAACTTCTACTTTCGTCAGTCCTTAACATCTACCTCTCTGAATTTTCATGAA  732
Query  474  TTTCTATTTCACAAGGGTAATTGTTTTATATACACTGGCAGCAGCATACAATAAAACTTA  533
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  733  TTTCTATTTCACAAGGGTAATTGTTTTATATACACTGGCAGCAGCATACAATAAAACTTA  792
Query  534  GTATGAAACTTT  545
            ||||||||||||















G proteins are trimeric proteins that regulate flow of 
information from cell surface receptors to internal
metabolic effectors. Interactions of a G protein with its
activated receptor promotes exchange of GTP for GDP 
(alpha subunit). The alpha-GTP complex dissociates
from the beta-gamma heterodimer so as to interact with 
and regulate effector molecules. G proteins are
involved as modulators or transducers in
transmembrane signaling systems. The beta and
gamma chains are required for the GTPase activity, for 
replacement of GDP by GTP, and for G protein-effector
interactions.
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Sanger sequencing (forward and reverse)
EMBOSS_001        51 TACCTGGGCACAGGACTTCAAAGCAAACACAGATTCCCCCTCCCCCTTAA    100
                                                     ||||||||||||||||||
PCR band         1 ATTCCCCCTCCCCCTTAA     18
EMBOSS_001       101 TATTTAAGAATTAAAAGATGATGAGAAATAAGGACAAAAGCCAAGAGGAG    150
                     ||||||||||||||||||||||||||||||||||||||||||||||||||
PCR band 19 TATTTAAGAATTAAAAGATGATGAGAAATAAGGACAAAAGCCAAGAGGAG     68
EMBOSS_001       151 GACAGTTCGCTACACAGCAATGCATCGAGGTGACCAAGAATATGGCCCAG    200
                     ||||||||||||||||||||||||||||||||||||||||||||||||||
PCR band 69 GACAGTTCGCTACACAGCAATGCATCGAGGTGACCAAGAATATGGCCCAG    118
EMBOSS_001       201 GTGACCAAAGCCCTGGACAAGGCCCTGAGCACCATGGACCTGCAGAAGGT    250
                     ||||||||||||||||||||||||||||||||||||||||||||||||||
PCR band 119 GTGACCAAAGCCCTGGACAAGGCCCTGAGCACCATGGACCTGCAGAAGGT    168
EMBOSS_001       251 CTCCTCAGTGATGGACAGGTTCGAGCAGCAGGTGCAGAACCTGGACGTCC    300
                     |||||||||||||||||||||||||||








>ref|NM_001271.3| Homo sapiens chromodomain helicase DNA binding protein 2 (CHD2), 
transcript variant 1, mRNA
Length=9374
GENE ID: 1106 CHD2| chromodomain helicase DNA binding protein 2 [Homo sapiens]
Score =  324 bits (358),  Expect = 3e-91
Identities = 179/179 (100%), Gaps = 0/179 (0%)
Strand=Plus/Plus
Query  1    CTACTAGTAGATAGGACTCTTGGTTTGGACATACTACATGGATCAGTAAATACCTGGGCA  60
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  459  CTACTAGTAGATAGGACTCTTGGTTTGGACATACTACATGGATCAGTAAATACCTGGGCA  518
Query  61   CAGGACTTCAAAGCAAACACAGATTCCCCCTCCCCCTTAATATTTAAGAATTAAAAGATG  120
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  519  CAGGACTTCAAAGCAAACACAGATTCCCCCTCCCCCTTAATATTTAAGAATTAAAAGATG  578
Query  121  ATGAGAAATAAGGACAAAAGCCAAGAGGAGGACAGTTCGCTACACAGCAATGCATCGAG  179
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||








/gene_synonym="CHMP1; KIAA0047; PCOLN3; PRSM1"
BLAST vs mRNA
>ref|NM_001083314.1| Homo sapiens chromatin modifying protein 1A (CHMP1A), transcript 
variant 1, mRNA
Length=2353
GENE ID: 5119 CHMP1A| chromatin modifying protein 1A [Homo sapiens]
Score = 1292 bits (1432),  Expect = 0.0
Identities = 814/878 (92%), Gaps = 14/878 (1%)
Strand=Plus/Plus
Ð 
Query  179   GGTGACCAAGAATATGGCCCAGGTGACCAAAGCCCTGGACAAGGCCCTGAGCACCATGGA  238
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  365   GGTGACCAAGAATATGGCCCAGGTGACCAAAGCCCTGGACAAGGCCCTGAGCACCATGGA  424
Query  239   CCTGCAGAAGGTCTCCTCAGTGATGGACAGGTTCGAGCAGCAGGTGCAGAACCTGGACGT  298
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  425   CCTGCAGAAGGTCTCCTCAGTGATGGACAGGTTCGAGCAGCAGGTGCAGAACCTGGACGT  484
Query  299   CCATACATCGGTGATGGAGGACTCCATGAGCTCGGCCACCACCCTGACCACGCCGCAGGA  358
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  485   CCATACATCGGTGATGGAGGACTCCATGAGCTCGGCCACCACCCTGACCACGCCGCAGGA  544
Query  359   GCAGGTGGACAGCCTCATCATGCAGATCGCCGAGGAGAATGGCCTGGAGGTGCTGGACCA  418
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  545   GCAGGTGGACAGCCTCATCATGCAGATCGCCGAGGAGAATGGCCTGGAGGTGCTGGACCA  604
Query  419   GCTCAGCCAGCTGCCCGAGGGCGCCTCTGCCGTGGGCGAGAGCTCTGTnnnnnnnnnnnn  478
   ||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  605   GCTCAGCCAGCTGCCCGAGGGCGCCTCTGCCGTGGGCGAGAGCTCTGTGCGCAGCCAGGA  664
Query  479 nnnnnnnnnnnnnnnnnnnnTGGCCGCCTTGAGGAACTAGCCGTGCCCCGCCGGTGTGCA  538
||||||||||||||||||||||||||||||||||||||||
Sbjct  665   GGACCAGCTGTCACGGAGGTTGGCCGCCTTGAGGAACTAGCCGTGCCCCGCCGGTGTGCA  724
Query  539   CCGCCTCTGCCCCGTGATGTGCTGGAAGGCTCCTGTCCTCTCCCCACCGCGTCTTGCCTT  598
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  725   CCGCCTCTGCCCCGTGATGTGCTGGAAGGCTCCTGTCCTCTCCCCACCGCGTCTTGCCTT  784
Query  599   TGTGCTGACCCCGCGGGGCTGCGGCCGGCAGCCACTCTGCGTCTCTCACCTGCCAGGCCT  658
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  785   TGTGCTGACCCCGCGGGGCTGCGGCCGGCAGCCACTCTGCGTCTCTCACCTGCCAGGCCT  844
Query  659   GCGTGGCCTTAGGGTTGTTCCTGTTCTTTTAGGTTGGGCGGTGGGTCTGTGTCCTGGTGT  718
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  845   GCGTGGCCTTAGGGTTGTTCCTGTTCTTTTAGGTTGGGCGGTGGGTCTGTGTCCTGGTGT  904
Query  719   TGAGTTTCTGCAAATTTCTGGGGGTGATTTCTGTGACTCTGGGCCCACAGCGGGGAGGCC  778
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  905   TGAGTTTCTGCAAATTTCTGGGGGTGATTTCTGTGACTCTGGGCCCACAGCGGGGAGGCC  964
Query  779   AAGAAGGGCCCTGTGGACTTTCACCCAGCACTGTGGGGGCCTTCAGACTCTGGGGCAGCA  838
             |||| |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  965   AAGAGGGGCCCTGTGGACTTTCACCCAGCACTGTGGGGGCCTTCAGACTCTGGGGCAGCA  1024
Query  839   GACATGCTGCTTCCCATCAG-CAGAGGGGGTCAGGCCTGCCCTGTTGCCAAACAACTCCT  897
             |||||||||||||||||||| |||||||||||||| ||||||||||||||||||||||| 
Summary for CHD2
The CHD family of proteins is characterized by the 
presence of chromo (chromatin organization
modifier) and SNF2-related helicase/ATPase
domains. CHD domains modify gene expression
by altering chromatin structure and access of the 
transcriptional apparatus to target DNA sites. HGF 
regulates cell growth, and cell motility and
modulates CHD2 activity.
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Sbjct  1025  GACATGCTGCTTCCCATCAGCCAGAGGGGGTCAGGGCTGCCCTGTTGCCAAACAACTCCC  1084
Query  898   TGAGGCCTCTCCGCACCAACTCATCGGGCAGGAGGTCTCACCCATGTTGGAC-GACATAG  956
             |||||||||||||||||| |||| ||||||||||||| || ||||| ||||| |||||||
Sbjct  1085  TGAGGCCTCTCCGCACCACCTCAGCGGGCAGGAGGTCCCA-CCATG-TGGACAGACATAG  1142
Query  957   CCCTAGGAGGACACCACAGGTCTAGTGTGGCTTGGGGGATGTCAGGT--CACTAAGC---  1011
             ||| |||||| ||||||||||||| ||||   |||||||||||||||  |||  | |
Sbjct  1143  CCCAAGGAGG-CACCACAGGTCTA-TGTGTGCTGGGGGATGTCAGGTGCCACCCAACGCT  1200
Query  1012  GTTCTGGGTGTATT--CAATGACATCCTTCCTTCTTCA  1047
             || ||||  |||||  ||||||||||| |||| || ||












EMBOSS_001  2 GTCAGAAGGGGAACGGATCTGTGTGCCCACAGCTCCTGGAGCCCCACAGC     51
                     ||||||||||||||||||||||||||||||||||||||||||||||||||
PCR band  2 GTCAGAAGGGGAACGGATCTGTGTGCCCACAGCTCCTGGAGCCCCACAGC  51
EMBOSS_001 52 AAAGAGTTGAAATTCACAAGCTGCGTCAAGGTGAGAACTTAATCCTGGGT    101
                     |||||||||||| |||||||||||||||||||||||||||||||||||||
PCR band 52 AAAGAGTTGAAATTCACAAGCTGCGTCAAGGTGAGAACTTAATCCTGGGT    101
EMBOSS_001       102 TTCAGCATTGGAGGTGGAAT 151
                     ||||||||||||||||||||





/gene_synonym="LRH-1; MGC47755; P2X5; P2X5R"
Summary for CHMP1A
CHMP1A a member of the CHMP/Chmp family. CHMP1A is a component of 
endosomal sorting transport complex III (ESCRT-III) which is involved in
multivesicular bodies (MVBs) formation and sorting of endosomal cargo proteins 
into MVBs. The MVB pathway appears to require the sequential function of ESCRT-
O, -I,-II and -III complexes. ESCRT-III proteins mostly dissociate from the
invaginating membrane before the ILV is released. The ESCRT machinery also 
functions in topologically equivalent membrane fission events, such as the terminal 
stages of cytokinesis and the budding of enveloped viruses (HIV -1). Involved in 
recruiting VPS4A and/or VPS4B to the midbody of dividing cells. May also be 
involved in chromosome condensation. Targets the Polycomb group (PcG) protein 
BMI1/PCGF4 to regions of condensed chromatin. 
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BLAST vs mRNA
>ref|NM_001204520.1| Gene info linked to NM_001204520.1 Homo sapiens purinergic receptor P2X, ligand-
gated ion channel, 5 (P2RX5), transcript variant 5, mRNA
Length=2269
GENE ID: 5026 P2RX5 | purinergic receptor P2X, ligand-gated ion channel, 5 [Homo sapiens]
Score =  244 bits (132),  Expect = 2e-63
Identities = 132/132 (100%), Gaps = 0/132 (0%)
Strand=Plus/Plus
Query  4     GCTCACATCTGGGCCAGGGCTGCTGGGGATGCCGGAGCAGCAGGAGCTGCAGGAGCCACC  63
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1455  GCTCACATCTGGGCCAGGGCTGCTGGGGATGCCGGAGCAGCAGGAGCTGCAGGAGCCACC  1514
Query  64    CGAGGCGAAGCGTGGAAGCAGCAGTCAGAAGGGGAACGGATCTGTGTGCCCACAGCTCCT  123
     ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1515  CGAGGCGAAGCGTGGAAGCAGCAGTCAGAAGGGGAACGGATCTGTGTGCCCACAGCTCCT  1574
Query  124   GGAGCCCCACAG  135
             ||||||||||||








>ref|NM_014604.3| Gene info linked to NM_014604.3 Homo sapiens Tax1 (human T-cell leukemia virus type 
I) binding protein 3 (TAX1BP3), transcript variant 1, mRNA
Length=1398
GENE ID: 30851 TAX1BP3 | Tax1 (human T-cell leukemia virus type I) binding protein 3 [Homo sapiens] 
Score = 1218 bits (659),  Expect = 0.0
Identities = 680/689 (99%), Gaps = 6/689 (0%)
Strand=Plus/Plus
Ð 
Query  135  GCAAAGAGTTGAAATTCACAAGCTGCGTCAAGGTGAGAACTTAATCCTGGGTTTCAGCAT  194
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  192  GCAAAGAGTTGAAATTCACAAGCTGCGTCAAGGTGAGAACTTAATCCTGGGTTTCAGCAT  251
Query  195  TGGAGGTGGAATCGACCAGGATCCTTCCCAGAATCCCTTCTCTGAAGACAAGACGGACAA  254
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  252  TGGAGGTGGAATCGACCAGGATCCTTCCCAGAATCCCTTCTCTGAAGACAAGACGGACAA  311
Query  255  GGGTATTTATGTCACACGGGTGTCTGAAGGAGGCCCTGCTGAAATCGCTGGGCTGCAGAT  314
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  312  GGGTATTTATGTCACACGGGTGTCTGAAGGAGGCCCTGCTGAAATCGCTGGGCTGCAGAT  371
Query  315  TGGAGACAAGATCATGCAGGTGAACGGCTGGGACATGACCATGGTCACACACGACCAGGC  374
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  372  TGGAGACAAGATCATGCAGGTGAACGGCTGGGACATGACCATGGTCACACACGACCAGGC  431
Query  375  CCGCAAGCGGCTCACCAAGCGCTCGGAGGAGGTGGTGCGTCTGCTGGTGACGCGGCAGTC  434
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  432  CCGCAAGCGGCTCACCAAGCGCTCGGAGGAGGTGGTGCGTCTGCTGGTGACGCGGCAGTC  491
Query  435  GCTGCAGAAGGCCGTGCAGCAGTCCATGCTGTCCTAGCAGCCACCACCATCTGCGACTCC  494
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  492  GCTGCAGAAGGCCGTGCAGCAGTCCATGCTGTCCTAGCAGCCACCACCATCTGCGACTCC  551
Query  495  TGCCTGCCGCCTCTCTGTACAGTAACGCCACTTCCACACTCTGTCCCCATCTGGCTTCTG  554
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  552  TGCCTGCCGCCTCTCTGTACAGTAACGCCACTTCCACACTCTGTCCCCATCTGGCTTCTG  611
Query  555  CTGACCGCTGGGCCCCAGCTCAGAAGGGCTATAGCTGGTCCCAGAGGCCTGGCCTGGCCT  614
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

















>ref|NM_152745.2| UniGene infoGeoGene info Homo sapiens neurexophilin 1 (NXPH1), mRNA
Length=2931
GENE ID: 30010 NXPH1 | neurexophilin 1 [Homo sapiens]
Score =  720 bits (798),  Expect = 0.0
Identities = 399/399 (100%), Gaps = 0/399 (0%)
Strand=Plus/Plus
Query  5    CAACTGTGCCAAGCCTTGGCTCCCGCGAACCAATCCTGAGCGCGACCCGGGCACTGGGAC  64
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  569  CAACTGTGCCAAGCCTTGGCTCCCGCGAACCAATCCTGAGCGCGACCCGGGCACTGGGAC  628
Query  65  GGCGACTCCGCCAAAGCTGGACGAGGCAGCCGGACCCGTCTGCGCTCGAGCATGGAGACG  124
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  629  GGCGACTCCGCCAAAGCTGGACGAGGCAGCCGGACCCGTCTGCGCTCGAGCATGGAGACG  688
Query  125  GAGCGCCTGGGAGGGCACGTCCGGGGCGCTGGAGACGCCAGGCCCGAGTAGCTTCTCCAT  184
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  689  GAGCGCCTGGGAGGGCACGTCCGGGGCGCTGGAGACGCCAGGCCCGAGTAGCTTCTCCAT  748
Query  185  GGAGCCTGCCCAGAGCGGTCCCTTCTCGCAGGATTCGCCCCAAGTCCTGTGCGGCTGCTG  244
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  749  GGAGCCTGCCCAGAGCGGTCCCTTCTCGCAGGATTCGCCCCAAGTCCTGTGCGGCTGCTG  808
Query  245  AGAGCGCTCCTTGCTCTGTAAAGTGGATGTCAGGTGGATCTATGTTTCTGAAGGAACAAA  304
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  809  AGAGCGCTCCTTGCTCTGTAAAGTGGATGTCAGGTGGATCTATGTTTCTGAAGGAACAAA  868
Query  305  GACTCAAAGAAGGCACCGCCAAGGAAGTTTGAGACGCGGGAGAATGCAGGCTGCGTGCTG  364
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  869  GACTCAAAGAAGGCACCGCCAAGGAAGTTTGAGACGCGGGAGAATGCAGGCTGCGTGCTG  928
Query  365  GTACGTGCTTTTCCTCCTGCAGCCCACCGTCTACTTGGT  403
            |||||||||||||||||||||||||||||||||||||||







/gene_synonym="DIB1; DIM1; HsT161; TXNL4; U5-15kD"
BLAST vs mRNA
>ref|NM_006701.2| Homo sapiens thioredoxin-like 4A (TXNL4A), mRNA
Length=1415
Score =  654 bits (724),  Expect = 0.0
Identities = 375/381 (98%), Gaps = 2/381 (0%)
Strand=Plus/Plus
Ð 
Query  401  GGTTAAAAATTTTGCAGTTATTTATCTTGTGGATATTACAGAAGTGCCTGACTTCAACAA  460
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  293  GGTTAAAAATTTTGCAGTTATTTATCTTGTGGATATTACAGAAGTGCCTGACTTCAACAA  352
Query  461  AATGTATGAGTTATACGATCCATGTACTGTCATGTTTTTCTTCAGGAACAAGCACATCAT  520
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  353  AATGTATGAGTTATACGATCCATGTACTGTCATGTTTTTCTTCAGGAACAAGCACATCAT  412
Query  521  GATTGACTTGGGGACTGGCAACAACAACAAGATTAACTGGGCCATGGAGGACAAGCAGGA  580
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  413  GATTGACTTGGGGACTGGCAACAACAACAAGATTAACTGGGCCATGGAGGACAAGCAGGA  472
Query  581  GATGGTGGACATCATCGAGACGGTGTACCGCGGGGCCCGCAAAGGCCGCGGCCTGGTGGT  640
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  473  GATGGTGGACATCATCGAGACGGTGTACCGCGGGGCCCGCAAAGGCCGCGGCCTGGTGGT  532
Query  641  GTCCCCCAAGGACTACTCCACCAAGTACCGCTACTGAGGCGCCCTCAGTCTGCGCGGATA  700
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  533  GTCCCCCAAGGACTACTCCACCAAGTACCGCTACTGAGGCGCCCTCAGTCTGCGCGGATA  592
Query  701  AATGTCGTGGAGACCTTTTTGTATAGAAACATATTTAAGCTATTTAAAGCCTTTGG-AAA  759
            |||||||||||| ||||||||||| ||||| | ||||||||||||||||||||||| |||
Sbjct  593  AATGTCGTGGAGCCCTTTTTGTATGGAAACGT-TTTAAGCTATTTAAAGCCTTTGGAAAA  651
Query  760  TACAGGAAGCTCCCGGGCTGG  780
            ||||||||||||| |||||||


















/gene_synonym="AD029; bA245H20.2; LSR7; RP11-245H20.2"
BLAST vs mRNA
>ref|NM_018559.2| Homo sapiens KIAA1704 (KIAA1704), mRNA
Length=1431
Score =  527 bits (584),  Expect = 2e-153
Identities = 292/292 (100%), Gaps = 0/292 (0%)
Strand=Plus/Plus
22
Query  5     CAGTAAGAAAGATGAAGAACATATATTATCAGGAAGAGATAAGAGACTGGCTGAGCAGGT  64
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  835   CAGTAAGAAAGATGAAGAACATATATTATCAGGAAGAGATAAGAGACTGGCTGAGCAGGT  894
Query  65    ATCTTCATACAATGAATCAAAAAGATCAGAATCTCTTATGGACATACATCATAAAAAGTT  124
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  895   ATCTTCATACAATGAATCAAAAAGATCAGAATCTCTTATGGACATACATCATAAAAAGTT  954
Query  125   AAAGAGTAAGGCTGCTGAAGACAAAAATAAGCCTCAAGAGAGAATACCATTTGACCGTGA  184
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  955   AAAGAGTAAGGCTGCTGAAGACAAAAATAAGCCTCAAGAGAGAATACCATTTGACCGTGA  1014
Query  185   TAAAGATCTCAAGGTTAATCGGTTTGATGAAGCTCAGAAAAAAGCCCTAATaaaaaaaTC  244
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1015  TAAAGATCTCAAGGTTAATCGGTTTGATGAAGCTCAGAAAAAAGCCCTAATAAAAAAATC  1074
Query  245   TAGAGAACTAAACACCAGATTTTCACACGGCAAAGGCAATATGTTTTTATAA  296
             ||||||||||||||||||||||||||||||||||||||||||||||||||||






/gene_synonym="CENP-R; CENPR; HSU37139; NRIF3; TAP20"
BLAST vs mRNA
>ref|NM_014288.3| Homo sapiens integrin beta 3 binding protein (beta3-endonexin) (ITGB3BP), mRNA
Length=892
Score =  241 bits (266),  Expect = 3e-67
Identities = 135/136 (99%), Gaps = 0/136 (0%)
Strand=Plus/Plus
Ð 
Query  293  ATAAATTCATGATGTTGCTATCAAAAGTTGAGAAATTGTCAGAAGAAATCATGGAGATAA  352
            || |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  282  ATGAATTCATGATGTTGCTATCAAAAGTTGAGAAATTGTCAGAAGAAATCATGGAGATAA  341
Query  353  TGCAAAATTTAAGTAGTATACAGGCTTTGGAGGGCAGTAGAGAGCTTGAAAATCTCATTG  412
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  342  TGCAAAATTTAAGTAGTATACAGGCTTTGGAGGGCAGTAGAGAGCTTGAAAATCTCATTG  401
Query  413  GAATCTCCTGTGCATC  428
            ||||||||||||||||

















/gene_synonym="DDX8; HRH1; PRP22; PRPF22"
BLAST vs mRNA
>ref|NM_004941.1| Homo sapiens DEAH (Asp-Glu-Ala-His) box polypeptide 8 (DHX8), mRNA
Length=4201
Gene id: 4826690 ATP-dependent RNA helicase DHX8
Score =  542 bits (600),  Expect = 2e-157
Identities = 300/300 (100%), Gaps = 0/300 (0%)
Strand=Plus/Plus
Query  2    TGGCTGTAGCCATGGCGGGAGCCTTAATCGGGTCGGAGCCAGGCCCCGCGGAAGAACTTG  61
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  81   TGGCTGTAGCCATGGCGGGAGCCTTAATCGGGTCGGAGCCAGGCCCCGCGGAAGAACTTG  140
Query  62   CCAAACTCGAGTACCTGTCTTTGGTGTCAAAGGTTTGCACTGAGCTGGACAATCACTTGG  121
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  141  CCAAACTCGAGTACCTGTCTTTGGTGTCAAAGGTTTGCACTGAGCTGGACAATCACTTGG  200
Query  122  GGATCAACGACAAGGACCTTGCTGAATTTGTGATCAGTCTTGCTGAGAAAAATACCACCT  181
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  201  GGATCAACGACAAGGACCTTGCTGAATTTGTGATCAGTCTTGCTGAGAAAAATACCACCT  260
Query  182  TTGATACTTTTAAGGCTTCTCTCGTCAAAAATGGTGCAGAATTTACGGATTCTCTTATTA  241
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  261  TTGATACTTTTAAGGCTTCTCTCGTCAAAAATGGTGCAGAATTTACGGATTCTCTTATTA  320
Query  242  GTAACTTGCTGCGTCTCATACAAACCATGCGGCCTCCAGCGAAGCCTTCCACTAGCAAAG  301
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||








>ref|NM_006721.2| Homo sapiens adenosine kinase (ADK), transcript variant ADK-long, mRNA
Length=2018
GENE ID: 132 ADK| adenosine kinase [Homo sapiens]
Score = 1088 bits (1206),  Expect = 0.0
Identities = 667/713 (93%), Gaps = 41/713 (5%)
Strand=Plus/Plus
Ð 
Query  300   AGGTTTTCTGTCTCAACTGGTCTCTGACAAGCCTCTGACTGAATGTATCCGTGCTGGCCA  359
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1035  AGGTTTTCTGTCTCAACTGGTCTCTGACAAGCCTCTGACTGAATGTATCCGTGCTGGCCA  1094
Query  360   CTATGCAGCAAGCATCATAATTAGACGGACTGGCTGCACCTTTCCTGAGAAGCCAGACTT  419
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 1095  CTATGCAGCAAGCATCATAATTAGACGGACTGGCTGCACCTTTCCTGAGAAGCCAGACTT  1154
24
Query  420   CCACTGATGGAAGAGCTGAAAACACAAGCCCAGGAGTGCAGACACTGCCCTAATTGCTTC  479
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1155  CCACTGATGGAAGAGCTGAAAACACAAGCCCAGGAGTGCAGACACTGCCCTAATTGCTTC  1214
Query  480   CTGAGAATTCCCATATTAATAAAGAAGAAAATTATCTGCCATTTTTTCCTACTATAATAA  539
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1215  CTGAGAATTCCCATATTAATAAAGAAGAAAATTATCTGCCATTTTTTCCTACTATAATAA  1274
Query  540   TGCTGAATCTTAATTTAGAGGGTACAAGGGTATGGTAATGCTTGTAGAATCTTTATTATC  599
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1275  TGCTGAATCTTAATTTAGAGGGTACAAGGGTATGGTAATGCTTGTAGAATCTTTATTATC  1334
Query  600   TCAACAATCTAAAAAATGATGTTTATTTCCATAGTTTGATAGTGCCACTTAAATGCCAAT  659
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1335  TCAACAATCTAAAAAATGATGTTTATTTCCATAGTTTGATAGTGCCACTTAAATGCCAAT  1394
Query  660   TAAACAAGAATATAACATTTCAATAGAAATTTTTATTTCATTTTCAATTACTTTGTA---  716
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1395  TAAACAAGAATATAACATTTCAATAGAAATTTTTATTTCATTTTCAATTACTTTGTAAAT  1454
Query  717 --------------------------------TACATTTCTGCTTTGAATGCAGATGCAA  744
                                             ||||||||||||||||||||||||||||
Sbjct  1455  TCGTGTGTATTTAGTACACTGATTTGTTTTTTTACATTTCTGCTTTGAATGCAGATGCAA  1514
Query  745   ATTTTAATATAATAGATTTTTTAATGAATTAATCTTAACATAGTAATCTTTAGCTTTTTA  804
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1515 --TTTAATATAATAGATTTTTTAATGAATTAATCTTAACATAGTAATCTTTAGCTTTTTA  1572
Query  805   TACAAATATATTTAATTTAGGAGTATATGTGTGTCTATACACACACATACATAAATATAC  864
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1573  TACAAATATATTTAATTTAGGAGTATATGTGTGTCTATACACACACATACATAAATATAC  1632
Query  865   CACATATACA-CTGATAGTCAAATAGGGTACAGAAATTTTATCTTGTCAA-TATGCC-AA  921
             |||||||||| |||||||||||||| |||||||||||||||||||||||| |||||| ||
Sbjct  1633  CACATATACACCTGATAGTCAAATAAGGTACAGAAATTTTATCTTGTCAATTATGCCAAA  1692
Query  922   TTATCTCTTTAATGTGCACTCCAACATGTAAT-AACTTTGGATATTTAAAAAA  973
             | ||||||||||||||||||| |||||||||| ||||||||||| ||||| ||


















/gene_synonym="CGI-124; CYPL1; hCyPX; MGC678; PPIase"
BLAST vs mRNA
>ref|NM_016059.4| Homo sapiens peptidylprolyl isomerase (cyclophilin)-like 1 (PPIL1), mRNA
Length=1750
GENE ID: 51645 PPIL1| peptidylprolyl isomerase (cyclophilin)-like 1 [Homo sapiens] 
Score =  437 bits (484),  Expect = 3e-126
Identities = 242/242 (100%), Gaps = 0/242 (0%)
Strand=Plus/Plus
Query  12   CTAGACAAGCATTCCGCCGCCGGCTTCGCTATGGCGGCAATTCCCCCAGATTCCTGGCAG  71
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  223  CTAGACAAGCATTCCGCCGCCGGCTTCGCTATGGCGGCAATTCCCCCAGATTCCTGGCAG  282
25
Query  72   CCACCCAACGTTTACTTGGAGACCAGCATGGGAATCATTGTGCTGGAGCTGTACTGGAAG  131
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  283  CCACCCAACGTTTACTTGGAGACCAGCATGGGAATCATTGTGCTGGAGCTGTACTGGAAG  342
Query  132  CATGCTCCAAAGACCTGTAAGAACTTTGCTGAGTTGGCTCGTCGAGGTTACTACAATGGC  191
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  343  CATGCTCCAAAGACCTGTAAGAACTTTGCTGAGTTGGCTCGTCGAGGTTACTACAATGGC  402
Query  192  ACAAAATTCCACAGAATTATCAAAGACTTCATGATCCAAGGAGGTGACCCAACAGGGACA  251
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  403  ACAAAATTCCACAGAATTATCAAAGACTTCATGATCCAAGGAGGTGACCCAACAGGGACA  462
Query  252  GG  253
            ||








>ref|NM_020950.1| Homo sapiens KIAA1614 (KIAA1614), mRNA
Length=4155
GENE ID: 57710 KIAA1614| KIAA1614 [Homo sapiens]
Score = 1238 bits (1372),  Expect = 0.0
Identities = 712/724 (98%), Gaps = 4/724 (0%)
Strand=Plus/Plus
Ð 
Query  252   GGAGGACCCCAGGGCTTTCTTGGCTCAGCAGATGTTGCCACCATCAACTCCACGGGCATC  311
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  2828  GGAGGACCCCAGGGCTTTCTTGGCTCAGCAGATGTTGCCACCATCAACTCCACGGGCATC  2887
Query  312   ACCCTCTCCCTGTCCTCAGAGGAGTCAGAGTCCAGCAAGGAATCAGAGGGAAGCCTGCAG  371
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  2888  ACCCTCTCCCTGTCCTCAGAGGAGTCAGAGTCCAGCAAGGAATCAGAGGGAAGCCTGCAG  2947
Query  372   AGGACAGGGTCAGGATCTGGAGGACATGTGCTGTCAAGAGCATCAGCAGGAGCTGGCACA 431
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  2948  AGGACAGGGTCAGGATCTGGAGGACATGTGCTGTCAAGAGCATCAGCAGGAGCTGGCACA  3007
Query  432   GGACCCGGCTCCCCCTCGGCTGCCCCTTTGGACCAGAACAAGAAAAGGAGCAGCAGCATA  491
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  3008  GGACCCGGCTCCCCCTCGGCTGCCCCTTTGGACCAGAACAAGAAAAGGAGCAGCAGCATA  3067
Query  492   GCCTCCACCCTGGGGCTGAAAAAGCTCTTCTCAGCCCTGGGCCAGAGTTCCCGGCCCAAG  551
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  3068  GCCTCCACCCTGGGGCTGAAAAAGCTCTTCTCAGCCCTGGGCCAGAGTTCCCGGCCCAAG  3127
Query  552   CTGGGCAAGTCCCGCAGCTACAGTGTGGAGCAGTTGCAGCCCGCCCCGCCTGGCCTGACG  611
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  3128  CTGGGCAAGTCCCGCAGCTACAGTGTGGAGCAGTTGCAGCCCGCCCCGCCTGGCCTGACG  3187
Query  612   TCACAGTCCAGGGCCCCATCGTTACAATCCCTGCACCCGGTGTCACCCTCTCACCAGCGT  671
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  3188  TCACAGTCCAGGGCCCCATCGTTACAATCCCTGCACCCGGTGTCACCCTCTCACCAGCGT  3247
Query  672   CGGAAAGCTGCCTCTTTTCAGAACCTCCATTCTCTGCTGAGCAGCAAGGGGGACCGGTCC  731
             ||||||||||||||||||||||||||||||||||||||||||||||||||| ||||||||
Sbjct  3248  CGGAAAGCTGCCTCTTTTCAGAACCTCCATTCTCTGCTGAGCAGCAAGGGGAACCGGTCC  3307
Query  732   AGCCTCTACCTGGTAGCAGGGCCAGGGGACCACAGTGCAGCTGGCA-GCCGGCCAAGACT  790
             |||||||||||||||||||||||||||||||||||||||||||||| |||||||||||||
Sbjct  3308  AGCCTCTACCTGGTAGCAGGGCCAGGGGACCACAGTGCAGCTGGCAGGCCGGCCAAGACT  3367
Query  791   TCACCACGGCGTGCCCTCAGTGTGGAGGACGTGGGTGCTCCCAGCCTGTCTCGCACCGTG  850
             |||||||||||||||||||||||||||||||||||||||||||||||| |||||||||||
Sbjct  3368  TCACCACGGCGTGCCCTCAGTGTGGAGGACGTGGGTGCTCCCAGCCTGGCTCGCACCGTG  3427
Query  851   GGCCGCCTGGTGGAGGTGTTCCCAGACAGCACCAGCCAGCTGCAGCTGCAGCGCTCTCCA  910
             ||||||||||||||||||||||||||| |||||||||||||||||||||||||||| |||
Sbjct  3428  GGCCGCCTGGTGGAGGTGTTCCCAGACGGCACCAGCCAGCTGCAGCTGCAGCGCTCCCCA  3487
26
Query  911 -AGGGCACTTTCGGCTTCTGCGT-GCCTCTGGGAAT-GGCGCCCAGACTCAGGGACGCAC  967
               ||||||||||||||||||||| |||||||||||| |||||||||||||||| | || |
Sbjct  3488  GGGGGCACTTTCGGCTTCTGCGTGGCCTCTGGGAATGGGCGCCCAGACTCAGGTATGCCC  3547
Query  968   TCTC  971
             ||||




















>ref|NM_018034.2| Homo sapiens WD repeat domain 70 (WDR70), mRNA
Length=2247
Score =  334 bits (370),  Expect = 4e-95
Identities = 193/198 (97%), Gaps = 0/198 (0%)
Strand=Plus/Plus
Query  5    GGTTCTGCGGCGTGCGGCCAGCCATGGAGCGCTCTGGGCCCAGCGAAGTGACAGGCTCAG  64
            ||||||| || |||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  36   GGTTCTGGGGTGTGCGGCCAGCCATGGAGCGCTCTGGGCCCAGCGAAGTGACAGGCTCAG  95
Query  65   ACGCATCGGGACCGGACCCGCAGCTTGCGGTCACCATGGGCTTCACGGGGTTCGGTAAAA  124
            |||| |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  96   ACGCGTCGGGACCGGACCCGCAGCTTGCGGTCACCATGGGCTTCACGGGGTTCGGTAAAA  155
Query  125  AAGCTCGCACATTTGACTTGGAAGCAATGTTTGAACAAACTCGAAGAACAGCTGTGGAAA  184
            |||||||||||||||||||||||||||||||||||||||||||||| |||||||||||||
Sbjct  156  AAGCTCGCACATTTGACTTGGAAGCAATGTTTGAACAAACTCGAAGGACAGCTGTGGAAA  215
Query  185  GAAGTTGCAAAACACTGG  202
            ||||| ||||||||||||







/gene_synonym="FLJ22280; FLJ36132; KIAA0692; LEMD7"
BLAST vs mRNA
>ref|NM_015114.1| Homo sapiens ankyrin repeat and LEM domain containing 2 (ANKLE2), mRNA
Length=4491
GENE ID: 23141 ANKLE2 | ankyrin repeat and LEM domain containing 2 [Homo sapiens]
Score = 1517 bits (1682),  Expect = 0.0
Identities = 986/1049 (93%), Gaps = 45/1049 (4%)
Strand=Plus/Plus
Ð 
Query  202   GGTGAAATGACAATGGATGCTCTGTTGGCTCGATTGAAACTTCTGAATCCAGATGACCTT  261
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  248   GGTGAAATGACAATGGATGCTCTGTTGGCTCGATTGAAACTTCTGAATCCAGATGACCTT  307
Query  262   AGAGAAGAAATCGTCAAAGCCGGATTGAAATGTGGACCCATTACATCAACTACAAGGTTC  321
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  308   AGAGAAGAAATCGTCAAAGCCGGATTGAAATGTGGACCCATTACATCAACTACAAGGTTC  367
Query  322   ATTTTTGAGAAAAAATTGGCTCAGGCTTTACTGGAGCAAGGAGGAAGGCTGTCTTCTTTC  381
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  368   ATTTTTGAGAAAAAATTGGCTCAGGCTTTACTGGAGCAAGGAGGAAGGCTGTCTTCTTTC  427
Query  382   TACCACCATGAGGCAGGTGTCACAGCTCTCAGCCAGGACCCACAAAGGATTTTGAAGCCA  441
        ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  428   TACCACCATGAGGCAGGTGTCACAGCTCTCAGCCAGGACCCACAAAGGATTTTGAAGCCA  487
Query  442   GCTGAAGGGAACCCAACTGATCAGGCTGGTTTTTCTGAAGACAGAGATTTTGGTTACAGT  501
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  488   GCTGAAGGGAACCCAACTGATCAGGCTGGTTTTTCTGAAGACAGAGATTTTGGTTACAGT  547
Query  502   GTGGGCCTGAATCCTCCAGAGGAGGAAGCTGTGACATCCAAGACCTGCTCGGTGCCTCCT  561
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||| |||
Sbjct  548   GTGGGCCTGAATCCTCCAGAGGAGGAAGCTGTGACATCCAAGACCTGCTCGGTGCCCCCT  607
Query  562   AGTGACACCGACACCTACAGAGCTGGAGCGACTGCGTCTAAGGAGCCGCCCCTGTACTAT  621
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  608   AGTGACACCGACACCTACAGAGCTGGAGCGACTGCGTCTAAGGAGCCGCCCCTGTACTAT  667
Query  622   GGGGTGTGTCCAGTGTATGAGGACGTCCCAGCGAGAAATGAAAGGATCTATGTTTATGAA  681
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  668   GGGGTGTGTCCAGTGTATGAGGACGTCCCAGCGAGAAATGAAAGGATCTATGTTTATGAA  727
Query  682   AATAAAAAGGAAGCATTGCAAGCTGTCAAGATGATCAAAGGGTCCCGATTTAAAGCTTTT  741
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  728   AATAAAAAGGAAGCATTGCAAGCTGTCAAGATGATCAAAGGGTCCCGATTTAAAGCTTTT  787
Query  742   TCTACCAGAGAAGACGCTGAGAAATTTGCTAGAGGAATTTGTGATTATTTCCCTTCTCCA  801
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  788   TCTACCAGAGAAGACGCTGAGAAATTTGCTAGAGGAATTTGTGATTATTTCCCTTCTCCA  847
Query  802   AGCAAAACGTCCTTACCACTGTCTCCTGTGAAAACAGCTCCACTCTTTAGCAATGACAGG  861
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  848   AGCAAAACGTCCTTACCACTGTCTCCTGTGAAAACAGCTCCACTCTTTAGCAATGACAGG  907
Query  862  TTGAAAGATGGTTTGTGCTTGTCGG-ATCAG-AACAGTCAACAAAGAGCGAGCGAACAGT  919
             ||||||||||||||||||||||||| ||||| ||||||||||||||||||||||||||||



















/gene_synonym="MGC:15243; PRO2134; TAF2I; TAFII28"
BLAST vs mRNA
>ref|NM_005643.2| Homo sapiens TAF11 RNA polymerase II, TATA box binding protein (TBP)-associated
factor, 28kDa (TAF11), mRNA
Length=1599
GENE ID: 6882 TAF11 | TAF11 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 28kDa 
[Homo sapiens]
Score =  405 bits (448),  Expect = 2e-116
Identities = 224/224 (100%), Gaps = 0/224 (0%)
Strand=Plus/Plus
Query  4    GCTTCTGCCTCAGGCATCTCCGCGATCTCCTCTCCCCTCCAATCCTATCCGTGATGGACG  63
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  33   GCTTCTGCCTCAGGCATCTCCGCGATCTCCTCTCCCCTCCAATCCTATCCGTGATGGACG  92
Query  64   ATGCCCACGAGTCGCCCTCCGACAAAGGTGGAGAGACAGGGGAGTCGGATGAGACGGCCG  123
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  93   ATGCCCACGAGTCGCCCTCCGACAAAGGTGGAGAGACAGGGGAGTCGGATGAGACGGCCG  152
Query  124  CTGTGCCCGGGGACCCGGGGGCTACCGACACCGATGGAATCCCAGAGGAAACTGACGGAG  183
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  153  CTGTGCCCGGGGACCCGGGGGCTACCGACACCGATGGAATCCCAGAGGAAACTGACGGAG  212
Query  184  ACGCAGATGTGGACTTGAAAGAAGCTGCAGCGGAGGAAGGCGAG  227
            ||||||||||||||||||||||||||||||||||||||||||||








>ref|NM_020728.2| Homo sapiens family with sequence similarity 62 (C2 domain containing) member B 
(FAM62B), mRNA
Length=5957
GENE ID: 57488 FAM62B | family with sequence similarity 62 (C2 domain containing) member B [Homo 
sapiens]
Score = 1321 bits (1464),  Expect = 0.0
Identities = 802/828 (96%), Gaps = 18/828 (2%)
Strand=Plus/Plus
Ð 
Query  217   AGGAAGGCGAGATTCGATACAAAACCAATGAACCTGTGTGGGAGGAAAACTTCACTTTCT  276
             ||||  || |||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1694  AGGAGAGCAAGATTCGATACAAAACCAATGAACCTGTGTGGGAGGAAAACTTCACTTTCT  1753
29
Query  277   TCATTCACAATCCCAAGCGCCAGGACCTTGAAGTTGAGGTCAGAGACGAGCAGCACCAGT  336
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1754  TCATTCACAATCCCAAGCGCCAGGACCTTGAAGTTGAGGTCAGAGACGAGCAGCACCAGT  1813
Query  337   GTTCCCTGGGGAACCTGAAGGTCCCCCTCAGCCAGCTGCTCACCAGTGAGGACATGACTG  396
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1814  GTTCCCTGGGGAACCTGAAGGTCCCCCTCAGCCAGCTGCTCACCAGTGAGGACATGACTG  1873
Query  397   TGAGCCAGCGCTTCCAGCTCAGTAACTCGGGTCCAAACAGCACCATCAAGATGAAGATTG  456
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1874  TGAGCCAGCGCTTCCAGCTCAGTAACTCGGGTCCAAACAGCACCATCAAGATGAAGATTG  1933
Query  457   CCCTGCGGGTGCTCCATCTCGAAAAGCGAGAAAGGCCTCCAGACCACCAACACTCAGCTC  516
      ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1934  CCCTGCGGGTGCTCCATCTCGAAAAGCGAGAAAGGCCTCCAGACCACCAACACTCAGCTC  1993
Query  517   AAGTCAAACGTCCCTCTGTGTCCAAAGAGGGGAGGAAAACATCCATCAAATCTCATATGT  576
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1994  AAGTCAAACGTCCCTCTGTGTCCAAAGAGGGGAGGAAAACATCCATCAAATCTCATATGT  2053
Query  577   CTGGGTCTCCAGGCCCTGGTGGCAGCAACACAGCTCCATCCACACCAGTCATTGGGGGCA  636
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  2054  CTGGGTCTCCAGGCCCTGGTGGCAGCAACACAGCTCCATCCACACCAGTCATTGGGGGCA  2113
Query  637   GTGATAAGCCTGGTATGGAAGAAAAGGCCCAGCCCCCTGAGGCCGGCCCTCAAGGGCTGC  696
             |||||||||||||||||||||||||||||||||||||||||||||||||||| |||||||
Sbjct  2114  GTGATAAGCCTGGTATGGAAGAAAAGGCCCAGCCCCCTGAGGCCGGCCCTCAGGGGCTGC  2173
Query  697   ACGACCT-GGCAGAAGCTCCTCCAGCCTCCTGGCCTCCCCAGGCCACATCTCAGTCAAGG  755
             ||||||| ||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  2174  ACGACCTGGGCAGAAGCTCCTCCAGCCTCCTGGCCTCCCCAGGCCACATCTCAGTCAAGG  2233
Query  756   AGCCGACCCCCAGCATCGCCTCGGACATCTCGCTGCCCATCGCCACCCAGGAGCTGCGGC  815
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||














>ref|NM_015462.3| Homo sapiens nucleolar protein 11 (NOL11), mRNA
Length=2454
GENE ID: 25926 NOL11 | nucleolar protein 11 [Homo sapiens]
Score =  484 bits (536),  Expect = 2e-140
Identities = 275/278 (98%), Gaps = 1/278 (0%)
Strand=Plus/Plus
Query  5    CTTGGGGAGCTGGTCAGTGAAACAAGGTCAAATTATAACATGTCCAGCTGTGTGCAACTT  64
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  162  CTTGGGGAGCTGGTCAGTGAAACAAGGTCAAATTATAACATGTCCAGCTGTGTGCAACTT  221
Query  65   TCAAACTGGAGAGTATGTTGTTGTACACGATAATAAGGTTTTAAGAATATGGAATAATGA  124
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  222  TCAAACTGGAGAGTATGTTGTTGTACACGATAATAAGGTTTTAAGAATATGGAATAATGA  281
Query  125  AGATGTAAACCTGGATAAAGTATTTAAAGCTACATTGTCAGCAGAAGTATATAGGATACT  184
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  282  AGATGTAAACCTGGATAAAGTATTTAAAGCTACATTGTCAGCAGAAGTATATAGGATACT  341
Query  185  TTCAGTGCAAGGGACAGAACCCTTGGTGCTCTTCAAGGAAGGTGCTGTTCGTGGTTTAGA 244
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  342  TTCAGTGCAAGGGACAGAACCCTTGGTGCTCTTCAAGGAAGGTGCTGTTCGTGGTTTAGA  401
30
Query  245  GGCCTTGCTTGCAGACCCCCAGCAGAAAATTGAAACTGTTATCTCTGATGAAGAAGTGAT  304
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  402  GGCCTTGCTTGCAGACCCCCAGCAGAAAATTGAAACTGTTATCTCTGATGAAGAAGTGAT  461
Query  305  TAAA  308
            ||||








>ref|NM_017994.4| Homo sapiens chromosome 7 open reading frame 42 (C7orf42), mRNA
Length=4238
GENE ID: 55069 C7orf42| chromosome 7 open reading frame 42 [Homo sapiens]
Score =  475 bits (526),  Expect = 2e-137
Identities = 309/338 (91%), Gaps = 1/338 (0%)
Strand=Plus/Plus
Ð 
Query  308   ACAGCCACCGCACTGTGTTCCTGACACGTACAGCAACGCCACGCTCTGGTACAAGATCTT  367
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  861   ACAGCCACCGCACTGTGTTCCTGACACGTACAGCAACGCCACGCTCTGGTACAAGATCTT  920
Query  368   CACAACTGCCAGAGATGCCAACACAAAATACGCCCAAGATTACAATCCTTTCTGGTGTTA  427
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  921   CACAACTGCCAGAGATGCCAACACAAAATACGCCCAAGATTACAATCCTTTCTGGTGTTA  980
Query  428   TAAGGGGGCCATTGGAAAAGTCTATCATGCTTTAAATCCCAAGCTTACAGTGATTGTTCC  487
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  981   TAAGGGGGCCATTGGAAAAGTCTATCATGCTTTAAATCCCAAGCTTACAGTGATTGTTCC  1040
Query  488   AGATGATGACCGTTCATTAATAAATTTGCATCTCATGCACACCAGTTACTTCCTCTTTGT  547
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1041  AGATGATGACCGTTCATTAATAAATTTGCATCTCATGCACACCAGTTACTTCCTCTTTGT  1100
Query  548   GATGGTGATAACAATGTTTTGCTATGCTGTTATCAAGGGCAGACCTAGCAAATTGCGTCA  607
    ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1101  GATGGTGATAACAATGTTTTGCTATGCTGTTATCAAGGGCAGACCTAGCAAATTGCGTCA  1160
Query  608   GAGCAATCCTGAATTTTGTCCCGAGAAGGTGGCTTTGGCTGAAGCCTAATTCCACAGCTC  667
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1161  GAGCAATCCTGAATTTTGTCCCGAGAAGGTGGCTTTGGCTGAAGCCTAATTCCACAGCTC  1220
Query  668   CTTGTTTTTAGAGAGAGACTGAGAGAACCATAATCCTTGCCTGCTGAACCCAGCCTGGGC  727
             ||||||||| ||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1221  CTTGTTTTTTGAGAGAGACTGAGAGAACCATAATCCTTGCCTGCTGAACCCAGCCTGGGC  1280
Query  728   CTGGATGCTCTGTGAATACATTATCTTGCGATGTTGGGTTATTCCAGCCAAAGACATTTC  787
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1281  CTGGATGCTCTGTGAATACATTATCTTGCGATGTTGGGTTATTCCAGCCAAAGACATTTC  1340
Query  788   AAGTGCCTGTAACTGATTTGTACATATTTAT-AAAATCTATTCAGA  832
             ||||||||||||||||||||||||||||||| ||||||||||||||













/gene_synonym="FLJ99347; MGC129801; NSUN5B; WBSCR20B"
BLAST vs mRNA
>ref|NR_033322.2| Homo sapiens NOP2/Sun domain family, member 5 pseudogene 1 (NSUN5P1), non-coding RNA
Length=1751
GENE ID: 155400 NSUN5P1| NOP2/Sun domain family, member 5 pseudogene 1 [Homo sapiens]
Score =  311 bits (168),  Expect = 3e-84
Identities = 168/168 (100%), Gaps = 0/168 (0%)
Strand=Plus/Plus
Query  5    GCCGCCAGGGCTCTATCAAGGGGCTGGTGTACTCCAGCAACTTCCAGAACGTGAAGCAGC  64
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  74   GCCGCCAGGGCTCTATCAAGGGGCTGGTGTACTCCAGCAACTTCCAGAACGTGAAGCAGC  133
Query  65   TGTACGCGCTGGTGTGCGAAACGCAGCGCTACTCCGCCGTGCTGGATGCCGTGATCTCCA  124
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  134  TGTACGCGCTGGTGTGCGAAACGCAGCGCTACTCCGCCGTGCTGGATGCCGTGATCTCCA  193
Query  125  GCGCCGGCCTCCTCAGTGCGAAGAAGCTGCAGCCGCACCTGGCCAAGG  172
            ||||||||||||||||||||||||||||||||||||||||||||||||






/gene_synonym="CPSF; CPSF-73; CPSF73; YSH1"
BLAST vs mRNA
>ref|NM_016207.2| Homo sapiens cleavage and polyadenylation specific factor 3, 73kDa (CPSF3), mRNA
Length=2286
Score =  609 bits (674),  Expect = 5e-178
Identities = 343/347 (98%), Gaps = 0/347 (0%)
Strand=Plus/Plus
Ð 
Query  169   AAGGGTGCAGTACAGAAGGTTTTTAAAAAATTAGAAATGCACGTTTACAGCAAGAGGTTG  228
             || ||||||||||||||||||| |||||||||||||||||||||||||||||||||||||
Sbjct  1818  AAAGGTGCAGTACAGAAGGTTTCTAAAAAATTAGAAATGCACGTTTACAGCAAGAGGTTG  1877
Query  229   GAGATCATGCTCCAGGACATATTTGGAGAAGACTGTGTAAGTGTAAAGGATGACTCTATT  288
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1878  GAGATCATGCTCCAGGACATATTTGGAGAAGACTGTGTAAGTGTAAAGGATGACTCTATT  1937
Query  289   TTTAGCGTCACAGTGGACGGGAAAACTGCCAACCTTAACTTGGAGACACGGACTGTAGAA  348
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1938  CTTAGCGTCACAGTGGACGGGAAAACTGCCAACCTTAACTTGGAGACACGGACTGTAGAA  1997
32
Query  349   TGTGAAGAGGGAAGTGAAGACGATGAATCCCTCCGAGAAATGGTGGAGCTGGCTGCACAG  408
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1998  TGTGAAGAGGGAAGTGAAGACGATGAATCCCTCCGAGAAATGGTGGAGCTGGCTGCACAG  2057
Query  409   AGACTGTACGAGGCCCTGACGCCAGTTCACTGAGACTGTGCCTGTATATGAACTTTGAAA  468
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  2058  AGACTGTACGAGGCCCTGACGCCAGTTCACTGAGACTGTGCCTGTATATGAACTTTGAAA  2117
Query  469   AAATACTTGACTTTACTTTTGTTACCTAAAATAAAATGCATTCGTTT  515
             |||||||||||| ||||||||||||||||||||||||||||||||||













/gene_synonym="HPC13; IGBF; MSP; MSPB; PN44; PRPS; PSP;
PSP-94; PSP57; PSP94"
BLAST vs mRNA
>ref|NM_002443.2| Homo sapiens microseminoprotein, beta- (MSMB), transcript variant PSP94, mRNA
Length=572
GENE ID: 4477 MSMB microseminoprotein, beta- [Homo sapiens]
Score =  423 bits (468),  Expect = 1e-122
Identities = 234/234 (100%), Gaps = 0/234 (0%)
Strand=Plus/Plus
Query  28  AGGAGTCCTGCTTATCACAATGAATGTTCTCCTGGGCAGCGTTGTGATCTTTGCCACCTT  87
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  14   AGGAGTCCTGCTTATCACAATGAATGTTCTCCTGGGCAGCGTTGTGATCTTTGCCACCTT  73
Query  88   CGTGACTTTATGCAATGCATCATGCTATTTCATACCTAATGAGGGAGTTCCAGGAGATTC  147
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  74   CGTGACTTTATGCAATGCATCATGCTATTTCATACCTAATGAGGGAGTTCCAGGAGATTC  133
Query  148  AACCAGGAAATGCATGGATCTCAAAGGAAACAAACACCCAATAAACTCGGAGTGGCAGAC  207
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  134  AACCAGGAAATGCATGGATCTCAAAGGAAACAAACACCCAATAAACTCGGAGTGGCAGAC  193
Query  208  TGACAACTGTGAGACATGCACTTGCTACGAAACAGAAATTTCATGTTGCACCCT  261
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||









>ref|NM_019896.2| Homo sapiens polymerase (DNA-directed), epsilon 4 (p12 subunit) (POLE4), mRNA
Length=710
GENE ID: 56655 POLE4| polymerase (DNA-directed), epsilon 4 (p12 subunit) [Homo sapiens] 
Score =  654 bits (724),  Expect = 0.0
Identities = 364/365 (99%), Gaps = 0/365 (0%)
Strand=Plus/Plus
Ð 
Query  262  ATAATGCAATAGAAGCTGTGGATGAATTTGCTTTTCTGGAAGGTACTTTAGATTGATTGC  321
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  331  ATAATGCAATAGAAGCTGTGGATGAATTTGCTTTTCTGGAAGGTACTTTAGATTGATTGC  390
Query  322  CGAGCGGGGCAGTTTTGTGAGCCTTCATCTGAAGCCTTCAGTTCACCCCTCTGCACAGGC  381
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  391  CGAGCGGGGCAGTTTTGTGAGCCTTCATCTGAAGCCTTCAGTTCACCCCTCTGCACAGGC  450
Query  382  CTCAGCTTTGAAGAACGGAGTCTTTGCACTTACACACACTCTTCCTGTTCTGCCTTCACC  441
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  451  CTCAGCTTTGAAGAACGGAGTCTTTGCACTTACACACACTCTTCCTGTTCTGCCTTCACC  510
Query  442  TATGCCGGGATAAGCAGAGATCTCATCAATTAGCTCTTCTCTGCAAGGTCTTCCACTGTT  501
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||| ||
Sbjct  511  TATGCCGGGATAAGCAGAGATCTCATCAATTAGCTCTTCTCTGCAAGGTCTTCCACTATT  570
Query  502  TCTGTCTGTCTTCCATATCAAGCCTGGATGCAGCTGCTGCTGCTTAGAGCAGAGATGAAG  561
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  571  TCTGTCTGTCTTCCATATCAAGCCTGGATGCAGCTGCTGCTGCTTAGAGCAGAGATGAAG  630
Query  562  AAAGTGTTCTGCATAAGTGGCTTCCTGAATGATGAGGACCAGAATAAAGGTTTTTGATCA  621
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  631  AAAGTGTTCTGCATAAGTGGCTTCCTGAATGATGAGGACCAGAATAAAGGTTTTTGATCA  690
Query  622  ACCTC  626
            |||||




















>ref|NM_001185.3| UniGene info linked to NM_001185.3GEO profiles info linked to NM_001185.3Gene info 
linked to NM_001185.3Genome view with mapviewer linked to NM_001185.3 Homo sapiens alpha-2-glycoprotein
1, zinc-binding (AZGP1), mRNA
Length=1278
GENE ID: 563 AZGP1 | alpha-2-glycoprotein 1, zinc-binding [Homo sapiens]
Score =  614 bits (332),  Expect = 2e-174
Identities = 332/332 (100%), Gaps = 0/332 (0%)
Strand=Plus/Plus
34
Query  5    AGAATGGTGCCTGTCCTGCTGTCTCTGCTGCTGCTTCTGGGTCCTGCTGTCCCCCAGGAG  64
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  99   AGAATGGTGCCTGTCCTGCTGTCTCTGCTGCTGCTTCTGGGTCCTGCTGTCCCCCAGGAG  158
Query  65   AACCAAGATGGTCGTTACTCTCTGACCTATATCTACACTGGGCTGTCCAAGCATGTTGAA  124
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  159  AACCAAGATGGTCGTTACTCTCTGACCTATATCTACACTGGGCTGTCCAAGCATGTTGAA  218
Query  125  GACGTCCCCGCGTTTCAGGCCCTTGGCTCACTCAATGACCTCCAGTTCTTTAGATACAAC  184
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  219  GACGTCCCCGCGTTTCAGGCCCTTGGCTCACTCAATGACCTCCAGTTCTTTAGATACAAC  278
Query  185  AGTAAAGACAGGAAGTCTCAGCCCATGGGACTCTGGAGACAGGTGGAAGGAATGGAGGAT  244
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  279  AGTAAAGACAGGAAGTCTCAGCCCATGGGACTCTGGAGACAGGTGGAAGGAATGGAGGAT  338
Query  245  TGGAAGCAGGACAGCCAACTTCAGAAGGCCAGGGAGGACATCTTTATGGAGACCCTGAAA  304
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  339  TGGAAGCAGGACAGCCAACTTCAGAAGGCCAGGGAGGACATCTTTATGGAGACCCTGAAA  398
Query  305  GACATCGTGGAGTATTACAACGACAGTAACGG  336
            ||||||||||||||||||||||||||||||||






/gene_synonym="CX29; CX30.2; CX31.3; GJE1"
BLAST vs mRNA
>ref|NM_181538.2| UniGene info linked to NM_181538.2GEO profiles info linked to NM_181538.2Gene info 
linked to NM_181538.2Genome view with mapviewer linked to NM_181538.2 Homo sapiens gap junction 
protein, gamma 3, 30.2kDa (GJC3), mRNA
Length=1131
GENE ID: 349149 GJC3 | gap junction protein, gamma 3, 30.2kDa [Homo sapiens]
Score = 1266 bits (685),  Expect = 0.0
Identities = 806/857 (95%), Gaps = 37/857 (4%)
Strand=Plus/Plus
Ð 
Query  337   ATGTGTGGCAGGTTCCTGCGGCGGCTGCTGGCGGAGGAGAGCCGGCGCTCCACCCCCGTG  396
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1     ATGTGTGGCAGGTTCCTGCGGCGGCTGCTGGCGGAGGAGAGCCGGCGCTCCACCCCCGTG  60
Query  397   GGGCGCCTCTTGCTTCCCGTGCTCCTGGGATTCCGCCTTGTGCTGCTGGCTGCCAGTGGG  456
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  61    GGGCGCCTCTTGCTTCCCGTGCTCCTGGGATTCCGCCTTGTGCTGCTGGCTGCCAGTGGG  120
Query  457   CCTGGAGTCTATGGTGATGAGCAGAGTGAATTCGTGTGTCACACCCAGCAGCCGGGCTGC  516
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  121  CCTGGAGTCTATGGTGATGAGCAGAGTGAATTCGTGTGTCACACCCAGCAGCCGGGCTGC  180
Query  517   AAGGCTGCCTGCTTCGATGCCTTCCACCCCCTCTCCCCGCTGCGTTTCTGGGTCTTCCAG  576
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  181   AAGGCTGCCTGCTTCGATGCCTTCCACCCCCTCTCCCCGCTGCGTTTCTGGGTCTTCCAG  240
Query  577   GTCATCTTGGTGGCTGTACCCAGCGCCCTCTATATGGGTTTCACTCTGTATCACGTGATC  636
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  241   GTCATCTTGGTGGCTGTACCCAGCGCCCTCTATATGGGTTTCACTCTGTATCACGTGATC  300
Query  637   TGGCACTGGGAATTATCAGGAAAGGGGAAGGAGGAGGAGATCTCTGATCCAGGGACGGGA  696
             |||||||||||||||||||||||||||||||||||||||| | |||||||||||||||||
Sbjct  301   TGGCACTGGGAATTATCAGGAAAGGGGAAGGAGGAGGAGACC-CTGATCCAGGGACGGGA  359
Query  697   GGGCAACACAGATGTCTCTAGGGGCTGGAAGCTCTCACGCTGCTCTGGGCTTATGTGGCT  756
             |||||||||||||||| | ||||||||||||| |||| ||||||||||||||||||||||
Sbjct  360   GGGCAACACAGATGTCCC-AGGGGCTGGAAGC-CTCAGGCTGCTCTGGGCTTATGTGGCT  417
Query  757   CAGCTGGGGGCTCGGCTTGTCCTGTAGGGGGCAGCCCTGGGGTTGCAGTACCACCTGTAT  816
             |||||||||||||||||||||||| |||||||||||||||||||||||||||||||||||
Sbjct  418   CAGCTGGGGGCTCGGCTTGTCCTGGAGGGGGCAGCCCTGGGGTTGCAGTACCACCTGTAT  477
35
Query  817   GGGTTCCAGATGCCCAGCTCCTTTGCATGTCGCCGAGAACCTTGCCTTGGTAGTATAACC  876
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  478   GGGTTCCAGATGCCCAGCTCCTTTGCATGTCGCCGAGAACCTTGCCTTGGTAGTATAACC  537
Query  877   TGCAATCTGTCCCGCTCCTCTGAGAAGACCATTTTTCCTAAAGACCATGTTTGGAGTCAG  936
             ||||||||||||||| ||||||||||||||||||| ||||||||||||||||||||||||
Sbjct  538   TGCAATCTGTCCCGCCCCTCTGAGAAGACCATTTT-CCTAAAGACCATGTTTGGAGTCAG  596
Query  937   CGGTTTCTGTCTCTTGTTTACTTTTTTGGAGCTTGTGCTTCTGGGTTTGGGGAGATGGTG  996
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||


















/gene_synonym="D10S105E; GDA; GDC; HGT.1; hML7; MGC39851; ML7"
BLAST vs mRNA
>ref|NM_152707.3| Homo sapiens solute carrier family 25 (mitochondrial carrier; Graves disease 
autoantigen), member 16 (SLC25A16), nuclear gene encoding mitochondrial protein, mRNA
Length=2264
GENE ID: 8034 SLC25A16 solute carrier family 25 (mitochondrial carrier; Graves disease autoantigen), member 
16 [Homo sapiens]
Score =  327 bits (177),  Expect = 3e-88
Identities = 177/177 (100%), Gaps = 0/177 (0%)
Strand=Plus/Plus
Query  5    TACCCTTCTTGGCAGACCTTCATCAGACAATCCTAATGTCTTAGTTTTGAAAACTCATGT  64
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  814  TACCCTTCTTGGCAGACCTTCATCAGACAATCCTAATGTCTTAGTTTTGAAAACTCATGT  873
Query  65   AAACTTACTTTGTGGTGGTGTTGCTGGAGCAATAGCGCAGACAATATCCTACCCATTTGA  124
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  874  AAACTTACTTTGTGGTGGTGTTGCTGGAGCAATAGCGCAGACAATATCCTACCCATTTGA  933
Query  125  TGTGACTCGTCGGCGAATGCAATTAGGAACTGTTCTGCCGGAATTTGAAAAGTGCCT  181
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||






/gene_synonym="DNA2L; FLJ10063; KIAA0083; MGC133297"
BLAST vs mRNA
>ref|NM_001080449.2| Gene info linked to NM_001080449.2 Homo sapiens DNA replication helicase 2 homolog 
(yeast) (DNA2), mRNA
Length=4287
GENE ID: 1763 DNA2 | DNA replication helicase 2 homolog (yeast) [Homo sapiens]
Score = 1496 bits (810),  Expect = 0.0
Identities = 933/984 (95%), Gaps = 41/984 (4%)
Strand=Plus/Plus
Ð 
Query  180   CTATTTCAGAAGAAAGTGGTAGCTTCCTTTCCAAGAACAGTTCTGAGCACAGGAATGGAT  239
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  182   CTATTTCAGAAGAAAGTGGTAGCTTCCTTTCCAAGAACAGTTCTGAGCACAGGAATGGAT  241
Query  240   AACCGGTACCTGGTGTTGGCAGTCAATACTGTACAGAACAAAGAGGGAAACTGTGAAAAG  299
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  242   AACCGGTACCTGGTGTTGGCAGTCAATACTGTACAGAACAAAGAGGGAAACTGTGAAAAG  301
Query  300   CGCCTGGTCATCACTGCTTCACAGTCACTAGAAAATAAAGAACTATGCATCCTTAGGAAT  359
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  302   CGCCTGGTCATCACTGCTTCACAGTCACTAGAAAATAAAGAACTATGCATCCTTAGGAAT  361
Query  360   GACTGGTGTTCTGTTCCAGTAGAGCCAGGAGATATCATTCATTTGGAGGGAGACTGCACA  419
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  362   GACTGGTGTTCTGTTCCAGTAGAGCCAGGAGATATCATTCATTTGGAGGGAGACTGCACA  421
Query  420   TCTGACACTTGGATAATAGATAAAGATTTTGGATATTTGATTCTGTATCCAGACATGCTG  479
  ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  422   TCTGACACTTGGATAATAGATAAAGATTTTGGATATTTGATTCTGTATCCAGACATGCTG  481
Query  480   ATTTCTGGCACCAGCATAGCCAGTAGTATTCGATGTATGAGAAGAGCTGTCCTGAGTGAA  539
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  482   ATTTCTGGCACCAGCATAGCCAGTAGTATTCGATGTATGAGAAGAGCTGTCCTGAGTGAA  541
Query  540   ACTTTTAGGAGCTCTGATCCAGCCACACGCCAAATGCTAATTGGTACGGTTCTCCATGAG  599
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  542   ACTTTTAGGAGCTCTGATCCAGCCACACGCCAAATGCTAATTGGTACGGTTCTCCATGAG  601
Query  600   GTGTTTCAAAAAGCAATAAATAATAGCTTTGCCCCAGAAAAGCTACAAGAACTTGCTTTT  659
             |||||||||||||| |||||||||||||||||||||||||||||||||||||||||||||
Sbjct  602   GTGTTTCAAAAAGCCATAAATAATAGCTTTGCCCCAGAAAAGCTACAAGAACTTGCTTTT  661
Query  660   CAAACAATTCAAGAA-TAAGACATTTGAAGGAAATGTACCGCTTAAATCTAAGTCAAGAT  718
             ||||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||
Sbjct  662   CAAACAATTCAAGAAATAAGACATTTGAAGGAAATGTACCGCTTAAATCTAAGTCAAGAT  721
Query  719   GAAATAAAACAAGAAGTAGAGGACTATCTTCCTTCGTTTTGTAAATGGGCAGGAGATTTC  778
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  722   GAAATAAAACAAGAAGTAGAGGACTATCTTCCTTCGTTTTGTAAATGGGCAGGAGATTTC  781
Query  779   ATGCATAAAAACACTTCGACTGACTTCCCTCAGATGCAGCTCTCTCTGCCAAGTGATAAT  838
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
















>ref|NM_001130727.1| UniGene info linked to NM_001130727.1GEO profiles info linked to NM_001130727.1 
Gene info linked to NM_001130727.1Genome view with mapviewer linked to NM_001130727.1 Homo sapiens 
PARK2 co-regulated-like (PACRGL), transcript variant 2, mRNA
Length=1796
GENE ID: 133015 PACRGL | PARK2 co-regulated-like [Homo sapiens]
Score =  394 bits (213),  Expect = 1e-108
Identities = 221/225 (99%), Gaps = 0/225 (0%)
Strand=Plus/Plus
Query  156  GGAGTGAAAGGGAAGCAATGCAAAAATCAAAGGGCTCTGGAGGTACACAGTTGAAAAACA  215
            |||||||||||||||||||||| |||||| ||||||||||||||||||||||||||||||
Sbjct  375  GGAGTGAAAGGGAAGCAATGCAGAAATCAGAGGGCTCTGGAGGTACACAGTTGAAAAACA  434
Query  216  GAGCAACAGGTAACTATGATCAAAGGACATCATCAAGCACACAGTTAAAACACAGGAATG  275
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  435  GAGCAACAGGTAACTATGATCAAAGGACATCATCAAGCACACAGTTAAAACACAGGAATG  494
Query  276 CAGTTCAGGGAAGCAAATCCTCATTGTCAACCAGTTCTCCAAAGTCTGCAAGAAAACTTC  335
            ||||||||||||||||||||||||||||||||||||||||| ||||||||||||||||||
Sbjct  495  CAGTTCAGGGAAGCAAATCCTCATTGTCAACCAGTTCTCCAGAGTCTGCAAGAAAACTTC  554
Query  336  ATCCTAAACCAAGTGATAAACTGAACCCTAAAACAATTAATCCGG  380
            |||||| ||||||||||||||||||||||||||||||||||||||








>ref|NM_001112720.1| UniGene info linked to NM_001112720.1GEO profiles info linked to 
NM_001112720.1Gene info linked to NM_001112720.1Genome view with mapviewer linked to NM_001112720.1 
Homo sapiens LIM and calponin homology domains 1 (LIMCH1), transcript variant 5, mRNA
Length=5722
GENE ID: 22998 LIMCH1 | LIM and calponin homology domains 1 [Homo sapiens]
Score =  472 bits (255),  Expect = 7e-132
Identities = 258/259 (99%), Gaps = 1/259 (0%)
Strand=Plus/Plus
Ð 
Query  379  GGAGCACCAGCATGTTTGACATGCGGTGTGAGGAGGAGGCCGCGGTGCAGCCGCACAGCA  438
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  646  GGAGCACCAGCATGTTTGACATGCGGTGTGAGGAGGAGGCCGCGGTGCAGCCGCACAGCA  705
Query  439  GGGCCCGCCAGGAGCAGCTGCAGCTGATAAATAACCAGCTGAGGGAAGAGGACGACAAAT  498
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  706  GGGCCCGCCAGGAGCAGCTGCAGCTGATAAATAACCAGCTGAGGGAAGAGGACGACAAAT  765
Query  499  GGCAAGATGACCTGGCTCGTTGGAAGAGTCGTAGAAGAAGTGTTTCTCAGGACTTAATCA  558
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  766  GGCAAGATGACCTGGCTCGTTGGAAGAGTCGTAGAAGAAGTGTTTCTCAGGACTTAATCA  825
Query  559  AGAAAGAGGAAGAAAGGaaaaaaaTGGAGAAGTTACTGGCTGGAGAAAGATGGGACAAGT  618
            ||||||||||||||||||||||||||||||||||||||||||||||| ||||||||||||
Sbjct  826  AGAAAGAGGAAGAAAGGAAAAAAATGGAGAAGTTACTGGCTGGAGAA-GATGGGACAAGT  884
Query  619  GAACGAAGGAAAAGCATCA  637
            |||||||||||||||||||



















/gene_synonym="TRP32; Txl; TXL-1; TXNL"
BLAST vs mRNA
>ref|NR_024546.1| Gene info linked to NR_024546.1Genome view with mapviewer linked to NR_024546.1 Homo 
sapiens thioredoxin-like 1 (TXNL1), transcript variant 2, non-coding RNA
Length=1434
GENE ID: 9352 TXNL1 | thioredoxin-like 1 [Homo sapiens]
Score =  957 bits (518),  Expect = 0.0
Identities = 523/525 (99%), Gaps = 2/525 (0%)
Strand=Plus/Plus
Query  5     CTTAGAAAATGACCTCTGAGAAGCAATGAGGACACAGATATTCCAAAAGGCTATATGGAT  64
             |||||||||||||| ||| |||||||||||||||||||||||||||||||||||||||||
Sbjct  672   CTTAGAAAATGACC-CTG-GAAGCAATGAGGACACAGATATTCCAAAAGGCTATATGGAT  729
Query  65    TTAATGCCTTTTATTAACAAAGCTGGTTGTGAATGTCTTAATGAAAGTGATGAGCATGGA  124
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  730   TTAATGCCTTTTATTAACAAAGCTGGTTGTGAATGTCTTAATGAAAGTGATGAGCATGGA  789
Query  125   TTTGACAACTGTTTACGAAAAGACACAACCTTCTTGGAATCTGACTGTGATGAACAGCTG  184
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  790   TTTGACAACTGTTTACGAAAAGACACAACCTTCTTGGAATCTGACTGTGATGAACAGCTG  849
Query  185   CTTATTACTGTGGCATTCAATCAACCTGTTAAGCTTTATTCCATGAAATTTCAAGGGCCA  244
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  850   CTTATTACTGTGGCATTCAATCAACCTGTTAAGCTTTATTCCATGAAATTTCAAGGGCCA  909
Query  245   GATAATGGTCAGGGCCCTAAATATGTAAAAATTTTTATCAACCTACCCCGATCTATGGAT  304
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  910   GATAATGGTCAGGGCCCTAAATATGTAAAAATTTTTATCAACCTACCCCGATCTATGGAT  969
Query  305   TTTGAAGAGGCAGAAAGAAGTGAACCAACTCAAGCTCTGGAACTGACAGAGGATGATATT  364
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  970   TTTGAAGAGGCAGAAAGAAGTGAACCAACTCAAGCTCTGGAACTGACAGAGGATGATATT  1029
Query  365   AAAGAAGATGGCATTGTTCCACTTCGTTATGTTAAGTTTCAGAATGTTAACAGTGTAACT  424
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1030  AAAGAAGATGGCATTGTTCCACTTCGTTATGTTAAGTTTCAGAATGTTAACAGTGTAACT  1089
Query  425   ATATTTGTTCAGTCGAATCAAGGTGAAGAGGAAACAACAAGAATTTCATATTTTACTTTT  484
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1090  ATATTTGTTCAGTCGAATCAAGGTGAAGAGGAAACAACAAGAATTTCATATTTTACTTTT  1149
Query  485   ATTGGTACTCCAGTCCAGGCAACAAATATGAATGACTTCAAACGA  529
             |||||||||||||||||||||||||||||||||||||||||||||







/gene_synonym="CD325; CDHN; CDw325; NCAD"
BLAST vs mRNA
>ref|NM_001792.3| UniGene info linked to NM_001792.3GEO profiles info linked to NM_001792.3Gene info 
linked to NM_001792.3Genome view with mapviewer linked to NM_001792.3 Homo sapiens cadherin 2, type 1, 
N-cadherin (neuronal) (CDH2), mRNA
Length=4380
GENE ID: 1000 CDH2 | cadherin 2, type 1, N-cadherin (neuronal) [Homo sapiens]
Score = 1000 bits (541),  Expect = 0.0
Identities = 634/673 (95%), Gaps = 29/673 (4%)
Strand=Plus/Plus
Ð 
Query  529   AAAAGTGCAACAGTATACGTTAATAATTCAAGCTACAGACATGGAAGGCAATCCCACATA  588
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1479  AAAAGTGCAACAGTATACGTTAATAATTCAAGCTACAGACATGGAAGGCAATCCCACATA  1538
Query  589   TGGCCTTTCAAACACAGCCACGGCCGTCATCACAGTGACAGATGTCAATGACAATCCTCC  648
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1539  TGGCCTTTCAAACACAGCCACGGCCGTCATCACAGTGACAGATGTCAATGACAATCCTCC  1598
Query  649   AGAGTTTACTGCCATGACGTTTTATGGTGAAGTTCCTGAGAACAGGGTAGACATCATAGT  708
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1599  AGAGTTTACTGCCATGACGTTTTATGGTGAAGTTCCTGAGAACAGGGTAGACATCATAGT  1658
Query  709   AGCTAATCTAACTGTGACCGATAA-GATCAACCCCATACACCAGCCTGGAACGCAGTGTA  767
             |||||||||||||||||||||||| |||||||||||||||||||||||||||||||||||
Sbjct  1659  AGCTAATCTAACTGTGACCGATAAGGATCAACCCCATACACCAGCCTGGAACGCAGTGTA  1718
Query  768   CAGAATCAGTGGCGGAGATCCTACTGGACGGTTCGCCATCCAGACCGACCCAAACAGCAA  827
      ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1719  CAGAATCAGTGGCGGAGATCCTACTGGACGGTTCGCCATCCAGACCGACCCAAACAGCAA  1778
Query  828   CGACGGGTTAGTCACCGTGGTCAAAC-AATCGACTTTGAAACAAATAGGATGTTTGTCCT  886
             |||||||||||||||||||||||||| |||||||||||||||||||||||||||||||||
Sbjct  1779  CGACGGGTTAGTCACCGTGGTCAAACCAATCGACTTTGAAACAAATAGGATGTTTGTCCT  1838
Query  887   TACTGTTTGCTGCCGAAAAATCAAGTGCCATTAGCCAAGGGAATTCAGCACCCGCCTCAG  946
             ||||||| ||||| ||||| ||||||||||||||||||||||||||||||||||||||||
Sbjct  1839  TACTGTT-GCTGCAGAAAA-TCAAGTGCCATTAGCCAAGGGAATTCAGCACCCGCCTCAG  1896
Query  947   TCAACTGCAACCGTGTCTGTTACAGTTATTGACGTAAATGAAAACCCTTATTTTGCCCCC  1006
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||















>ref|NM_001404.4| UniGene info linked to NM_001404.4GEO profiles info linked to NM_001404.4Gene info 
linked to NM_001404.4Genome view with mapviewer linked to NM_001404.4 Homo sapiens eukaryotic 
translation elongation factor 1 gamma (EEF1G), mRNA
Length=1552
GENE ID: 1937 EEF1G | eukaryotic translation elongation factor 1 gamma [Homo sapiens]
Score =  398 bits (215),  Expect = 1e-109
Identities = 218/219 (99%), Gaps = 1/219 (0%)
Strand=Plus/Plus
Query  5     GGCCCAGTTTGATGCTAAAAAG-TTGCAGAGACCCAACCTAAAAAGGACACACCACGGAA  63
             |||||||||||||||||||||| |||||||||||||||||||||||||||||||||||||
Sbjct  785   GGCCCAGTTTGATGCTAAAAAGTTTGCAGAGACCCAACCTAAAAAGGACACACCACGGAA  844
Query  64    AGAGAAGGGTTCACGGGAAGAGAAGCAGAAGCCCCAGGCTGAGCGGAAGGAGGAGAAAAA  123
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  845   AGAGAAGGGTTCACGGGAAGAGAAGCAGAAGCCCCAGGCTGAGCGGAAGGAGGAGAAAAA  904
Query  124   GGCGGCTGCCCCTGCTCCTGAGGAGGAGATGGATGAATGTGAGCAGGCGCTGGCTGCTGA  183
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  905   GGCGGCTGCCCCTGCTCCTGAGGAGGAGATGGATGAATGTGAGCAGGCGCTGGCTGCTGA  964
Query  184   GCCCAAGGCCAAGGACCCCTTCGCTCACCTGCCCAAGAG  222
             |||||||||||||||||||||||||||||||||||||||








>ref|NM_024060.2| UniGene info linked to NM_024060.2GEO profiles info linked to NM_024060.2Gene info 
linked to NM_024060.2Genome view with mapviewer linked to NM_024060.2 Homo sapiens AHNAK nucleoprotein 
(AHNAK), transcript variant 2, mRNA
Length=1108
GENE ID: 79026 AHNAK | AHNAK nucleoprotein [Homo sapiens]
Score =  630 bits (341),  Expect = 9e-180
Identities = 345/347 (99%), Gaps = 0/347 (0%)
Strand=Plus/Plus
Ð 
Query  221   AGGACTGTAGAAGCGGCCAGGAAGAAAACCACCCCCTTTTAAGGTTGTTTTTGTGACCGT  280
             ||||||||||||||||||||||||||||||||||||| ||||||||||||||||||||||
Sbjct  741   AGGACTGTAGAAGCGGCCAGGAAGAAAACCACCCCCTCTTAAGGTTGTTTTTGTGACCGT  800
Query  281   TTTTTGGAGCATTGTTCTAAAAATGGGAAATTACATATTGCTGTGCCAAGGGCAACAAAC  340
             | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  801   TCTTTGGAGCATTGTTCTAAAAATGGGAAATTACATATTGCTGTGCCAAGGGCAACAAAC  860
Query  341   ACCTGCAGTTAAAGGAATACCTTCCGCGAGGCGGCTTTTCGGAGCATGCATGTTTATAGC  400
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  861   ACCTGCAGTTAAAGGAATACCTTCCGCGAGGCGGCTTTTCGGAGCATGCATGTTTATAGC  920
Query  401   TCCAGCCAGGCCAGACCGAGGGCTGCTGCATAAGCCCTGCTTGGTGCATTTCTTTACTTG  460
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  921   TCCAGCCAGGCCAGACCGAGGGCTGCTGCATAAGCCCTGCTTGGTGCATTTCTTTACTTG  980
Query  461   CAAGGGGACAGAGTGTGGGCTTAGGTTTGGGACTAGAGGGGGCTTTGGCAACTATGGTGC  520
  ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  981   CAAGGGGACAGAGTGTGGGCTTAGGTTTGGGACTAGAGGGGGCTTTGGCAACTATGGTGC  1040
41
Query  521   TCAGGTGATTATCCTTCGCTCGTTTATCCAATAAACATTTATCAAGC  567
             |||||||||||||||||||||||||||||||||||||||||||||||















>ref|NM_001204141.1| Gene info linked to NM_001204141.1 Homo sapiens methyl-CpG binding domain protein 
1 (MBD1), transcript variant 10, mRNA
Length=2860
GENE ID: 4152 MBD1 | methyl-CpG binding domain protein 1 [Homo sapiens]
Score =  388 bits (210),  Expect = 7e-107
Identities = 215/217 (99%), Gaps = 2/217 (0%)
Strand=Plus/Plus
Query  1     TGGTGCCTGGCTGCCCTAGCAAGGCAGTAGACCCAGGCCTGCCTTCTGTGAAGCAAGAG-  59
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1849  TGGTGCCTGGCTGCCCTAGCAAGGCAGTAGACCCAGGCCTGCCTTCTGTGAAGCAAGAGC  1908
Query  60    CA-CTGACCCAGAGGAGGACAAGGAGGAGAACAAGGATGATTCTGCCTCCAAATTGGCCC  118
             || |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1909  CACCTGACCCAGAGGAGGACAAGGAGGAGAACAAGGATGATTCTGCCTCCAAATTGGCCC  1968
Query  119   CAGAGGAAGAGGCAGGAGGGGCTGGCACACCCGTGATCACGGAGATTTTCAGCCTGGGTG  178
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1969  CAGAGGAAGAGGCAGGAGGGGCTGGCACACCCGTGATCACGGAGATTTTCAGCCTGGGTG  2028
Query  179   GAACCCGCTTCCGAGATACAGCAGTCTGGTTGCCAAG  215
             |||||||||||||||||||||||||||||||||||||









>ref|NM_145020.3| UniGene info linked to NM_145020.3GEO profiles info linked to NM_145020.3Gene info 
linked to NM_145020.3Genome view with mapviewer linked to NM_145020.3 Homo sapiens coiled-coil domain 
containing 11 (CCDC11), mRNA
Length=1837
GENE ID: 220136 CCDC11 | coiled-coil domain containing 11 [Homo sapiens]
Score = 429 bits (232),  Expect = 4e-119
Identities = 232/232 (100%), Gaps = 0/232 (0%)
Strand=Plus/Plus
Ð 
Query  215  GAGATCCAAGCCTCCTAAAGGCCAAGGAGCTGAGCACCATCTAGAAAGAATCCGACGCAG  274
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  160  GAGATCCAAGCCTCCTAAAGGCCAAGGAGCTGAGCACCATCTAGAAAGAATCCGACGCAG  219
Query  275  CCATCAGAAGCATAATGCTATTTTGGCTTCCATTAAGTCAAGTGAGCGGGATCGCTTGAA  334
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  220  CCATCAGAAGCATAATGCTATTTTGGCTTCCATTAAGTCAAGTGAGCGGGATCGCTTGAA  279
Query  335  AGCTGAGTGGGACCAGCACAATGACTGCAAGATTTTGGACAGCCTTGTGCGAGCAAGAAT  394
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  280  AGCTGAGTGGGACCAGCACAATGACTGCAAGATTTTGGACAGCCTTGTGCGAGCAAGAAT  339
Query  395  CAAGGATGCTGTGCAAGGGTTTATCATTAACATTGAAGAAAGACGAAATAAG  446
      ||||||||||||||||||||||||||||||||||||||||||||||||||||















/gene_synonym="0610011B16Rik; CRN7; FLJ22021; FLJ44188; POD1"
BLAST vs mRNA
>ref|NM_001201473.1| Gene info linked to NM_001201473.1 Homo sapiens coronin 7 (CORO7), transcript 
variant 3, mRNA
Length=3599
GENE ID: 79585 CORO7 | coronin 7 [Homo sapiens]
Score =  435 bits (235),  Expect = 1e-120
Identities = 235/235 (100%), Gaps = 0/235 (0%)
Strand=Plus/Plus
Query  5     GGCGCTAATGGGCAGCCCTGGCTTCTCAGCCTGCAGCCTCCTGACATGAGCCCAGTGAGC  64
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  2727  GGCGCTAATGGGCAGCCCTGGCTTCTCAGCCTGCAGCCTCCTGACATGAGCCCAGTGAGC  2786
Query  65    CAAGCCCCCCGAGAGGCCCCTGCTCGTCGGGCCCCATCCTCAGCGCAGTACCTGGAAGAA  124
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  2787  CAAGCCCCCCGAGAGGCCCCTGCTCGTCGGGCCCCATCCTCAGCGCAGTACCTGGAAGAA  2846
Query  125   AAGTCTGACCAGCAAAAGAAGGAGGAGCTGCTGAATGCCATGGTGGCAAAACTGGGGAAC  184
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  2847  AAGTCTGACCAGCAAAAGAAGGAGGAGCTGCTGAATGCCATGGTGGCAAAACTGGGGAAC  2906
Query  185   CGGGAGGACCCACTCCCCCAGGACTCCTTTGAAGGCGTGGACGAGGACGAGTGGG  239
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||







/gene_synonym="CGI-136; MAGMAS; TIM16; TIMM16"
BLAST vs mRNA
>ref|NM_016069.9| Gene info linked to NM_016069.9 Homo sapiens presequence translocase-associated motor 
16 homolog (S. cerevisiae) (PAM16), nuclear gene encoding mitochondrial protein, mRNA
Length=600
GENE ID: 51025 PAM16 | presequence translocase-associated motor 16 homolog (S. cerevisiae) [Homo 
sapiens]
Score =  721 bits (390),  Expect = 0.0
Identities = 428/444 (97%), Gaps = 12/444 (2%)
Strand=Plus/Plus
Ð 
Query  238  GGCCAAGTACCTGGCCCAGATCATTGTGATGGGCGTGCAGGTGGTGGGCAGGGCCTTTGC  297
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  141  GGCCAAGTACCTGGCCCAGATCATTGTGATGGGCGTGCAGGTGGTGGGCAGGGCCTTTGC  200
Query  298  ACGGGCCTTGCGGCAGGAGTTTGCAGCCAGCCGGGCCGCAGCTGATGCCCGAGGACGCGC  357
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  201  ACGGGCCTTGCGGCAGGAGTTTGCAGCCAGCCGGGCCGCAGCTGATGCCCGAGGACGCGC  260
Query  358  TGGACACCGGTCTGCAGCCGCTTCCAACCTCTCCGGCCTCAGCCTCCAGGAGGCACAGCA  417
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  261  TGGACACCGGTCTGCAGCCGCTTCCAACCTCTCCGGCCTCAGCCTCCAGGAGGCACAGCA  320
Query  418  GATTCTCAACGTGTCCAAGCTGAGCTCTGAGGAGGTCCAGAAGA-CTATGAACACTTATT  476
            ||||||||||||||||||||||||| |||||||||||||||||| |||||||||||||||
Sbjct  321  GATTCTCAACGTGTCCAAGCTGAGCCCTGAGGAGGTCCAGAAGAACTATGAACACTTATT  380
Query  477  TAACGTGAATGATAAATCCGTGGGTGGCTCCTTCTACCTGCAGTCAAAGGTGGTCCGCGC  536
            ||| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  381  TAAGGTGAATGATAAATCCGTGGGTGGCTCCTTCTACCTGCAGTCAAAGGTGGTCCGCGC  440
Query  537  AAAGGAGCGCCTGGATGAGGAACTCAAAATCCAGGCCCAGGAG-ACAGAGAAAAAGG-CA  594
            ||||||||||||||||||||||||||||||||||||||||||| ||||||||||||| ||
Sbjct  441  AAAGGAGCGCCTGGATGAGGAACTCAAAATCCAGGCCCAGGAGGACAGAGAAAAAGGGCA  500
Query  595  GATGCCTCATACGTGACTGCTCG-CTCCCCC-GCC-ACCC-GC-GCCTCTAATTAATAGC  649
            |||||| |||||||||||||||| ||||||| ||| |||| || |||||||||| |||||
Sbjct  501  GATGCCCCATACGTGACTGCTCGGCTCCCCCCGCCCACCCCGCCGCCTCTAATTTATAGC  560
Query  650  T-G-TAATAA-TT-CTTTTCTGCA  669
            | | |||||| || ||||||||||


















/gene_synonym="ECGF; ECGF1; hPD-ECGF; MEDPS1; MNGIE; MTDPS1; PDECGF; TP"
BLAST vs mRNA
>ref|NM_001113756.1|  Homo sapiens thymidine phosphorylase (TYMP), transcript variant 3, mRNA
Length=1587
GENE ID: 1890 TYMP| thymidine phosphorylase [Homo sapiens]
Score =  881 bits (477),  Expect = 0.0
Identities = 477/477 (100%), Gaps = 0/477 (0%)
Strand=Plus/Plus
Query  5     CGCTCTGGTGGTGGACGTTAAGTTCGGAGGGGCCGCCGTCTTCCCCAACCAGGAGCAGGC  64
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  804   CGCTCTGGTGGTGGACGTTAAGTTCGGAGGGGCCGCCGTCTTCCCCAACCAGGAGCAGGC  863
Query  65    CCGGGAGCTGGCAAAGACGCTGGTTGGCGTGGGAGCCAGCCTAGGGCTTCGGGTCGCGGC  124
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  864   CCGGGAGCTGGCAAAGACGCTGGTTGGCGTGGGAGCCAGCCTAGGGCTTCGGGTCGCGGC  923
Query  125   AGCGCTGACCGCCATGGACAAGCCCCTGGGTCGCTGCGTGGGCCACGCCCTGGAGGTGGA  184
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  924   AGCGCTGACCGCCATGGACAAGCCCCTGGGTCGCTGCGTGGGCCACGCCCTGGAGGTGGA  983
Query  185   GGAGGCGCTGCTCTGCATGGACGGCGCAGGCCCGCCAGACTTAAGGGACCTGGTCACCAC  244
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  984   GGAGGCGCTGCTCTGCATGGACGGCGCAGGCCCGCCAGACTTAAGGGACCTGGTCACCAC  1043
Query  245   GCTCGGGGGCGCCCTGCTCTGGCTCAGCGGACACGCGGGGACTCAGGCCCAGGGCGCTGC  304
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1044  GCTCGGGGGCGCCCTGCTCTGGCTCAGCGGACACGCGGGGACTCAGGCCCAGGGCGCTGC  1103
Query  305   CCGGGTGGCCGCGGCGCTGGACGACGGCTCGGCCCTTGGCCGCTTCGAGCGGATGCTGGC  364
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1104  CCGGGTGGCCGCGGCGCTGGACGACGGCTCGGCCCTTGGCCGCTTCGAGCGGATGCTGGC  1163
Query  365   GGCGCAGGGCGTGGATCCCGGTCTGGCCCGAGCCCTGTGCTCGGGAAGTCCCGCAGAACG  424
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1164  GGCGCAGGGCGTGGATCCCGGTCTGGCCCGAGCCCTGTGCTCGGGAAGTCCCGCAGAACG  1223
Query  425   CCGGCAGCTGCTGCCTCGCGCCCGGGAGCAGGAGGAGCTGCTGGCGCCCGCAGATGG  481
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||








>ref|NM_001169110.1|  Homo sapiens SCO cytochrome oxidase deficient homolog 2 (yeast) (SCO2), nuclear 
gene encoding mitochondrial protein, transcript variant 3, mRNA
Length=1002
GENE ID: 9997 SCO2| SCO cytochrome oxidase deficient homolog 2 (yeast) [Homo sapiens] 
Score =  828 bits (448),  Expect = 0.0




Query  479   TGGAGCATCAGATCCATGCTGCTGCTGACTCGGAGCCCCACAGCTTGGCACAGGCTCTCT  538
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  144   TGGAGCATCAGATCCATGCTGCTGCTGACTCGGAGCCCCACAGCTTGGCACAGGCTCTCT  203
Query  539   CAGCTCAAGCCTCCGGTCCTCCCTGGGACCCTGGGAGGCCAGGCCCTGCATCTGAGGTCC  598
             ||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  204   CAGCTCAAGCCTCGGGTCCTCCCTGGGACCCTGGGAGGCCAGGCCCTGCATCTGAGGTCC  263
Query  599   TGGCTTTTGTCAAGGCAGGGCCCTGCAGAGACAGGTGGGCAGGGCCAGCCCCAGGGCCCT  658
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  264   TGGCTTTTGTCAAGGCAGGGCCCTGCAGAGACAGGTGGGCAGGGCCAGCCCCAGGGCCCT  323
Query  659   GGGCTTCGAACCCGGCTGCTGATCACAGGCCTGTTCGGGGCTGGACTCGGTGGGGCCTGG  718
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  324   GGGCTTCGAACCCGGCTGCTGATCACAGGCCTGTTCGGGGCTGGACTCGGTGGGGCCTGG  383
Query  719   CTGGCCCTGAGGGCTGAGAAGGAGAGGCTGCAGCAGCAAAAAGCGAACAGAAGCCCTGCG  778
             ||||||||||||||||||||||||||||||||||||||||| ||||||||||||||||||
Sbjct  384   CTGGCCCTGAGGGCTGAGAAGGAGAGGCTGCAGCAGCAAAA-GCGAACAGAAGCCCTGCG  442
Query  779   CCGGGCAGCTGTGGGCCAGGGGCGACTTCCACCTGCTGGATCACAGATGCCCGGGCTCGC  838
             || |||||||||||||||||| ||||||||||||||||||||||||| ||| ||||||||
Sbjct  443   CCAGGCAGCTGTGGGCCAGGG-CGACTTCCACCTGCTGGATCACAGAGGCC-GGGCTCGC  500
Query  839   TGCCAGGCTGACTTCCCGGGGCCAGTGGGTGCTGATGTACTTTGGCTTCCCTCCACTGCC  898
             ||| |||||||||||| |||||||||||||||||||||||||||||||| ||| ||||||
Sbjct  501   TGCAAGGCTGACTTCC-GGGGCCAGTGGGTGCTGATGTACTTTGGCTTCACTC-ACTGCC  558
Query  899   CCT-ACATCTGCCCAAAACAAACTGGAAAAAGCTTGGTGCAAGGTGGTGCGGGCAGCTGG  957
             | | ||||||||||| | | | ||||| || ||| |||||| |||||||||| |||||||
















>ref|NM_024664.2|  Homo sapiens phosphopantothenoylcysteine synthetase (PPCS), transcript variant 1, 
mRNA
Length=1489
GENE ID: 79717 PPCS| phosphopantothenoylcysteine synthetase [Homo sapiens]
Score =  612 bits (331),  Expect = 4e-174
Identities = 331/331 (100%), Gaps = 0/331 (0%)
Strand=Plus/Plus
Query  9    CCGCTTCCCACCCCAGACTTGGCTGTCCGCTCTGCGGCCTTCGGGCCCAGCCCTTTCGGG  68
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  346  CCGCTTCCCACCCCAGACTTGGCTGTCCGCTCTGCGGCCTTCGGGCCCAGCCCTTTCGGG  405
Query  69   CTTGCTGAGCCTGGAGGCCGAGGAGAATGCACTTCCGGGTTTTGCTGAGGCTCTGAGGAG  128
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  406  CTTGCTGAGCCTGGAGGCCGAGGAGAATGCACTTCCGGGTTTTGCTGAGGCTCTGAGGAG  465
Query  129  CTACCAGGAGGCTGCGGCTGCAGGCACCTTCCTGGCAGTAGAGTTCACCACTTTGGCGGA  188
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  466  CTACCAGGAGGCTGCGGCTGCAGGCACCTTCCTGGCAGTAGAGTTCACCACTTTGGCGGA  525
46
Query  189  CTATTTGCATCTGTTGCAGGCTGCGGCCCAGGCACTCAATCCGCTAGGCCCTTCTGCGAT  248
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  526  CTATTTGCATCTGTTGCAGGCTGCGGCCCAGGCACTCAATCCGCTAGGCCCTTCTGCGAT  585
Query  249  GTTTTACCTGGCTGCGGCTGTGTCAGATTTCTATGTTCCTGTCTCTGAAATGCCTGAACA  308
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  586  GTTTTACCTGGCTGCGGCTGTGTCAGATTTCTATGTTCCTGTCTCTGAAATGCCTGAACA  645
Query  309  CAAGATCCAGTCATCTGGGGGCCCACTGCAG  339
            |||||||||||||||||||||||||||||||




>ref|XR_113349.1| PREDICTED: Homo sapiens hypothetical LOC100507214 (LOC100507214), partial miscRNA
Length=668
GENE ID: 100507214 LOC100507214| hypothetical LOC100507214 [Homo sapiens]
Score =  544 bits (294),  Expect = 1e-153
Identities = 296/297 (99%), Gaps = 0/297 (0%)
Strand=Plus/Plus
Ð 
Query  338  AGGGAAAAGTTCAGTTAGAAGACATACTTCACCATCTTGAAAAAGAAGAAATCAATCCCC  397
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  371  AGGGAAAAGTTCAGTTAGAAGACATACTTCACCATCTTGAAAAAGAAGAAATCAATCCCC  430
Query  398  TTGCTACTACAGAAGAACAACTCTGTTTGGTGCTTATTCCAGCCAGCACAGTGAAGACAG  457
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  431  TTGCTACTACAGAAGAACAACTCTGTTTGGTGCTTATTCCAGCCAGCACAGTGAAGACAG  490
Query  458  GCTGAGGACTGCTACCACAGATGTAGAAGAGCTTATAGTGAAGCACATGGGTGAAACAAA  517
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  491  GCTGAGGACTGCTACCACAGATGTAGAAGAGCTTATAGTGAAGCACATGGGTGAAACAAA  550
Query  518  AGAAGTGAGAACTAATAGCATAGAATTTTAAAGACACCTGTGATTTTGTTCATTGCCCTT  577
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  551  AGAAGTGAGAACTAATAGCATAGAATTTTAAAGACACCTGTGATTTTGTTCATTGCCCTT  610
Query  578  CATTAAATTAACATATTAAAAACTAATGTTTGGCTATCACTGTATAGTTTGAAAAGC  634
            ||||||||| |||||||||||||||||||||||||||||||||||||||||||||||


















/gene_synonym="CTLH; FLJ12753; FLJ13910; FLJ21795; MGC78451; p44CTLH; RMD5"
BLAST vs mRNA
>ref|NM_022780.3| UniGene info linked to NM_022780.3GEO profiles info linked to NM_022780.3Gene info 
linked to NM_022780.3Genome view with mapviewer linked to NM_022780.3 Homo sapiens required for meiotic 
nuclear division 5 homolog A (S. cerevisiae) (RMND5A), mRNA
Length=6201
GENE ID: 64795 RMND5A | required for meiotic nuclear division 5 homolog A (S.
cerevisiae) [Homo sapiens]
Score = 1083 bits (586),  Expect = 0.0
Identities = 600/607 (99%), Gaps = 0/607 (0%)
Strand=Plus/Plus
Query  5    CGTGAAAACAAAAACAATCGGCCGCGCCGTCGCAGGCACCCGAACGTCGCGAGCGGGGCC  64
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  60   CGTGAAAACAAAAACAATCGGCCGCGCCGTCGCAGGCACCCGAACGTCGCGAGCGGGGCC  119
Query  65   TGGGGACGCGGGGCCGAGTGCAGCGAGCGAACGGGAGCAGCGGCGACTCGCCAgggggct  124
            ||||||||||| |||||||||||||||||||||||||||||||||||||||| |||||||
Sbjct  120  TGGGGACGCGGAGCCGAGTGCAGCGAGCGAACGGGAGCAGCGGCGACTCGCCGGGGGGCT  179
Query  125  agggcgccatggggcaggcgggctccggctgcgcggggctcccccggcgccgcggctagt  184
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  180  AGGGCGCCATGGGGCAGGCGGGCTCCGGCTGCGCGGGGCTCCCCCGGCGCCGCGGCTAGT  239
Query  185  gcgcccgccgcctcggccgcctcagcctcccgcgccgcccgcTTGGGGAACGAGGAGCAG  244
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  240  GCGCCCGCCGCCTCGGCCGCCTCAGCCTCCCGCGCCGCCCGCTTGGGGAACGAGGAGCAG  299
Query  245  GACGCGGCCTCGGCGGGGCCCGGGCCGAACGGCTGCGGACACCTGGGCGCCGAGGAGCCG  304
            ||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  300  GACGCGGCCTCGGTGGGGCCCGGGCCGAACGGCTGCGGACACCTGGGCGCCGAGGAGCCG  359
Query  305  AGCGCCGCCGCCTCCGGCATGGATCAGTGCGTGACGGTGGAGCGCGAGCTGGAGAAGGTG  364
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  360  AGCGCCGCCGCCTCCGGCATGGATCAGTGCGTGACGGTGGAGCGCGAGCTGGAGAAGGTG  419
Query  365  CTGCACAAGTTCTCGGGCTACGGGCAGCTGTGCGAGCGCGGCCTGGAGGAGCTCATCGAC  424
            |||||||||||||| |||||||||||||||||||||||||||||||||||||||||||||
Sbjct  420  CTGCACAAGTTCTCAGGCTACGGGCAGCTGTGCGAGCGCGGCCTGGAGGAGCTCATCGAC  479
Query  425  TACACCGGCGGTCTCAAGCACCAGATCCTGCAGAGCCACGGCCAAGATGCTGAATTATCA  484
            ||||||||||| ||||||||| ||||||||||||||||||||||||||||||||||||||
Sbjct  480  TACACCGGCGGCCTCAAGCACGAGATCCTGCAGAGCCACGGCCAAGATGCTGAATTATCA  539
Query  485  GGGACACTTTCACTTGTTTTGACACAGTGCTGTAAAAGAATAAAGGATACTGTTCAAAAA  544
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  540  GGGACACTTTCACTTGTTTTGACACAGTGCTGTAAAAGAATAAAGGATACTGTTCAAAAA  599
Query  545  TTGGCCTCCGACCACAAAGACATCCACAGCAGTGTTTCTCGGGTTGGAAAAGCCATTGAT  604
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  600  TTGGCCTCCGACCACAAAGACATCCACAGCAGTGTTTCTCGGGTTGGAAAAGCCATTGAT  659
Query  605  AAGGATT  611
            ||| |||








>ref|NM_022662.2| UniGene info linked to NM_022662.2GEO profiles info linked to NM_022662.2Gene info 
linked to NM_022662.2Genome view with mapviewer linked to NM_022662.2 Homo sapiens anaphase promoting 
complex subunit 1 (ANAPC1), mRNA
Length=6329
GENE ID: 64682 ANAPC1 | anaphase promoting complex subunit 1 [Homo sapiens]
Score =  510 bits (276),  Expect = 2e-143




Query  606   AGGATTCACTTTAAGAGATTTGGAAACTCTTCCCTTTGGAATTGCTCTTCCCATCAGAGA  665
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  3058  AGGATTCACTTTAAGAGATTTGGAAACTCTTCCCTTTGGAATTGCTCTTCCCATCAGAGA  3117
Query  666   TGCAATTTATCACTGTCGTGAACAGCCTGCCTCAGACTGGCCAGAAGCTGTCTGTCTCTT  725
             ||||||||||||||||||||| ||||||||||||||||||||||||||||||||||||||
Sbjct  3118  TGCAATTTATCACTGTCGTGAGCAGCCTGCCTCAGACTGGCCAGAAGCTGTCTGTCTCTT  3177
Query  726   GATTGGACGTCAGGATCTTTCCAAGCAGGCCTGCGAAGGAAACTTACTCAAAGG-A-GTC  783
             ||||||||||||||||||||||||||||||||||||||||||||||| |||||| | |||
Sbjct  3178  GATTGGACGTCAGGATCTTTCCAAGCAGGCCTGCGAAGGAAACTTACCCAAAGGGAAGTC  3237
Query  784   T--------AT--G-T-T-CCTTCAG-AACAGAAACTGAG-AGGAAGATGACGGCATGAA  828
             |        ||  | | | ||||||| ||||||||||||| |||||||||||||||||||
Sbjct  3238  TGTGCTCTCATCAGATGTTCCTTCAGGAACAGAAACTGAGGAGGAAGATGACGGCATGAA  3297
Query  829   TGACATGAATCACGAG-TCATGTCATTAATATGGAGTGA-GATTTATG--TGCAGG-TGT  883
      |||||||||||||||| |||||||||||||||||||||| |||||| |  |||||| |||
Sbjct  3298  TGACATGAATCACGAGGTCATGTCATTAATATGGAGTGAAGATTTAAGGGTGCAGGATGT  3357
Query  884   GCGAAGGCTTCTTCAGAGTGCGCATC-TGTCCGTGTCAT-GTAGTGCAGTACCC-GAGCT  940
             |||||||||||||||||||||||||| |||||||||||  |||||||||||||| |||||
Sbjct  3358  GCGAAGGCTTCTTCAGAGTGCGCATCCTGTCCGTGTCAACGTAGTGCAGTACCCAGAGCT  3417
Query  941   CA-TGACCACGAGT-CACTCGAAGGAAA-GGAA  970
             || ||||||||||| || |||| ||||| ||||
Sbjct  3418  CAGTGACCACGAGTTCA-TCGA-GGAAAAGGAA  3448
49
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